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The dissertation will discuss the advancement of informative structural biology 
techniques utilizing a top-down centric workflow with 193nm ultraviolet 
photodissociation (UVPD) mass spectrometry. Native electrospray ionization is used to 
transport proteins to the gas phase in a native-like state, then UVPD is used for structural 
characterization to reveal ligand binding sites within a protein-ligand complex as well as 
detect conformational changes based upon the suppression or enhancement of backbone 
cleavages. Conformational changes induced by ligand exchange or removal and single 
amino acid mutations as well as combinations of the two (ligands and mutations) are 
investigated. The rich fragmentation patterns of UVPD are also used for structural 
characterization of crosslinked proteins. Typically these crosslinking experiments are 
performed by bottom-up mass spectrometry with has significant shortcomings. The main 
drawback is the need for proteolysis which cuts proteins into small peptides, thus 
increasing the complexity of the samples and its subsequent analysis. Additionally this 
proteolysis step loses the post-translation modification information or amino acid 
mutations that may be driving a specific protein-protein interaction. Top-down methods 
 vii 
avoid protein digestion and thus are used to directly evaluate the protein interactions or 
protein complexes. These two methodologies will bring the mass spectrometry and 
structural biology community a step closer to the realization of high-throughput structural 
biology for proteins and their interactions with other proteins and small molecules.  
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Chapter 1:  Introduction 
 
1.1 INTRODUCTION 
Deciphering the structure of macromolecules such as proteins and DNA has 
consistently remained one of the most harrowing problems to be solved in the world of 
biochemistry. This dissertation focuses on developing mass spectrometry methods for 
protein structure characterization. To have a full appreciation for development of these 
new methods it is imperative that the history of using mass spectrometry in the context of  
structural biology needs to be assessed. There are four main categories of mass 
spectrometry methods applied for structural biology: covalent labeling for surface 
accessibility, covalent crosslinking of proteins, hydrogen-deuterium exchange, and native 
mass spectrometry. Two of these, covalent crosslinking and native mass spectrometry, 
were explored and improved upon with a top-down centric focus in the present 
dissertation.  
With the advent of x-ray crystallography1 the dream of generating three-
dimensional structures from precise analytical data had been achieved and since then has 
been adopted widely as the gold standard across the field of structural biology field as the 
gold standard.2,3 Additionally, nuclear magnetic resonance (NMR) has played a key role 
in determining in solution structures of proteins.4,5 While both of these methods have the 
potential to yield single amino acid resolution and side chain position, they also require 
potentially prohibitively large amounts of protein, up to mM concentrations and/or mg 
quantities, for data acquisition. While these techniques yield very high-resolution 
structures, they do not always reflect the native structure of the protein found at 
biologically relevant concentrations.6,7 These issues can lead to protein precipitation for 
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NMR and packing artifacts at key loops in the protein structure during crystallization. In 
addition to these issues, data analysis is complex and time-consuming, a factor that keeps 
these techniques from achieving a higher-throughput that could be used for screening the 
interactions of proteins containing unique amino acid substitutions with specific drugs or 
ligands or other proteins.  This is the intersection of structural biology where mass 
spectrometry can excel. Owing to its sensitivity, use of sub-microgram amounts of 
proteins, and its comparative ease of data analysis, mass spectrometry has many attributes 
that showcase its performance for protein structural analysis. The ability of mass 
spectrometry to quickly screen many combinations of protein-ligand interactions and to 
evaluate changes as a function of protein sequence or ligand identity compensates for the 
fact that the data obtained from mass spectrometry methods is low resolution and does 
not translate to three-dimensional representations.  With clever new strategies that 
combine labelling methods, computational modelling, and mass spectrometry detection , 
many low to mid resolution structural biology techniques have been developed over the 
past two decades. A number of these established and emerging methods will be surveyed 
in the following sections. 
1.2 COVALENT LABELING 
Covalent labeling is precisely what the name implies, using covalent labeling 
chemistry to decorate reactive and accessible amino acids on protein surfaces with 
trackable mass tags (ones that can be monitored by mass spectrometry based on mass 
shifts).  Two generalized strategies are possible:  solvent accessibility measurements8 and 
chemical crosslinking.8,9 With solvent accessibility, the protein is modified on its exposed 
surface by reactive small molecules.  The labelled protein is typically digested into more 
easily detected peptides which are separated and analyzed by LCMS/MS, and the 
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quantities of modified and unmodified sites are monitored based on the constituent 
peptides.8 The variations in the amounts of modified versus unmodified sites reflects the 
accessibility of different regions of the protein. On the other hand crosslinking uses fixed 
length crosslinking ligands to join together two available, reactive amino acids of a 
protein or pair of proteins in solution that are in close spatial proximity.  Subsequent mass 
spectrometric identification of the reacted amino acids is used to develop distance 
constraints for molecular modeling10 and determining protein-protein interactions for 
protein networking,11 as well as determining large macromolecular structures.12 
1.2.1 Solvent Accessibility 
Most commonly surface accessibility experiments take advantage of specific side 
chain chemistry to selectively label amino acids.8 There are numerous solvent 
accessibility probes that have been utilized for this type of mass spectrometry workflow, 
and several examples are shown in Figure 1.   
 
Figure 1. Common reagent(s) for covalent labeling of proteins that target (a) lysine, (b) 
arginine, (c) cysteine, (d) histidine, (e) tryptophan, (f) tyrosine, and (g,h) 




The ones in Figure 1a target primary amines (Lys and N-terminus) which is the most 
common reactive site for solvent accessibility studies.   The free amine on the N-terminus 
and side chain lysine are particularly  popular targets due to their high nucleophilicity. 
For example, historically acetic anhydride was used as a surface accessible labeling 
reagent.8,13 Another very popular way to label lysines comes from N-
hydroxysuccinimidyl (NHS) leaving group chemistry which has seen widespread use for 
these types of experiments.14,15 While lysine chemistry is very convenient there have also 
been specific chemistries developed for nearly all amino acid functionalities. These 
include modifications for acidic residues (glutamic and aspartic acid)8,16 (Figure 1g,h), 
arginine (Figure 1b),8,17,18 cysteine (Figure 1c),8,19 histidine (Figure 1d),8,20 tyrosine (Figure 
1f),8,21 and tryptophan (Figure 1e).8,22 There have also been several other chemistries 
optimized to be less specific labeling reagents using standard solution chemistry like 
diethylpyrocarbonate, DEPC, which has been shown to react with lysine, tyrosine, 
cysteine, arginine, serine, and threonine.23  Using less specific labels allows more sites to 
be modified in a single experiment, thus providing a greater array of solvent accessible 
site information at the expense of more complicated mixtures of peptides and more 
complex data analysis.   
There are two newly emerging techniques using laser activation to label non-
specifically across nearly all amino-acids which yields the most extensive amount of 
information as well as the fastest labeling time scale. This latter feature reduces the 
chance of structural distortion that slow labeling techniques may induce during the 
labeling process.15,24 The two methods  are laser-activated carbene footprinting25,26 and 
fast photochemical oxidation for proteins (FPOP) (Figure 2).27,28 Carbene footprinting 
uses a sterically strained diazirine ring or  one that is photoreactive with UV light .9,25,26 A 
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355 nm laser is pulsed for a fixed amount of time to activate the reagent in solution, and 
it reacts with accessible amino acids on a very rapid time-scale. Alternatively, the protein 
solution can be mixed with millimolar concentrations of peroxide which upon laser (250-
270 nm) irradiation produces OH radical species  (this is the FPOP method).28–30 These 
OH radical species react with any solvent-exposed residue that can be oxidized. Residues 
Gln, Glu, Asp, Asn, Ala, and Gly are relatively unreactive to hydroxyl radicals, but 
virtually all other amino acids are reactive.  Activated carbenes react with all amino acids 
and the protein backbone itself.26 
 
Figure 2. Generalized workflow for (a) fast photochemical oxidation of proteins (FPOP) 
and (b) carbene labeling.   
After the protein system has been labelled using one of the methods described 
above, it is generally digested using a specific protease such as trypsin to produce smaller 
peptides which are more easily analyzed than intact proteins. The modified peptide 
mixture is injected, separated, and peptides are identified by LC-MS/MS.8 Here the 
identified modified peptides are quantified relative to the corresponding unmodified 
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peptides in order to evaluate the reactivity of the various side-chains;  it is this relative 
reactivity which correlates with solvent accessibility (Figure 3a). Based on the quality of 
the MS2 spectra the reactivities of different sites (which are directly related to the rates of 
modification of each site) can be derived from the fragmentation patterns which display 
mass shifts in the fragment ions depending on the location of the chemical probe. There 
are also other solvent accessibility techniques that involve the use of isotopically encoded 
reactive tags which are used under a combination of denaturing and native conditions to 
label the protein.8,15,31  
 
Figure 3. Generalized workflow for surface accessibility measurement using (a) peak 
areas and (b) isotope ratios of labelled proteins.  
This generates a mixture of fully labelled peptides (denaturing conditions, one isotopic 
version of the reagent) versus partially labelled peptides (native conditions, a second 
isotopic version of the reagent), and the extent of modification in the native state is 
determined by comparison of the the peak abundances between the isotopically light and 
heavy generated versions of peptides (Figure 3b). This offers a more direct option for 
data processing in comparison to the methods that don’t utilize isotopic labelled reagents 
 7 
and thus handle quantitation based on quantitative comparison of modified and 
unmodified peptides.8  
1.2.2 Crosslinking Mass Spectrometry 
Alternatively to individually labeling reactive amino acids for information about 
their surface availability, a dual reactive covalent crosslinker can be used to determine 
residues near each other in two dimensional space.9 The length of the crosslinking arm 
provides a distance constraint between the reacted residues. These distance constraints 
can be used to aid structural modeling of proteins32 and protein complexes12 as well as 
provide a way to determine protein interaction networks when used in conjunction with 
more elaborate pulldown techniques used to isolate arrays of interacting proteins.11,33,34 
 
Figure 4. Examples of hombifunctional crosslinkers (a) disuccinimidyl-suberate (DSS) 
(b) bis(sulfosuccinimidyl) suberate (BS3) and (c) heterobifunctional 
crosslinker succinimidyl 6-(4,4’-azipentanamido)hexanoate) (LC-SDA).  
As with solvent accessibility measurements these chemical crosslinkers come in a 
wide assortment of flavors that can be customized for the the structural goal. The most 
commonly used crosslinker is disuccinimidyl suberate (DSS) which takes advantage of 
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NHS leaving groups to join two primary amine groups together.35 Bissulfosuccinimidyl 
suberate (BS3) is a water soluble analog of disuccinimidyl suberate (DSS) (Figure 4). 
These linkers both have a total distance constraint of 30 Å from Cα to Cα of the reactive 
residues (Figure 5).  
 
Figure 5. A generalized tri-peptide. The blue ovals indicate the peptide bonds and the red 
spheres indicate the alpha-carbons. 
The distance constraint is estimated by adding the length of the fully extended crosslinker 
to the length of the amino acid sidechains plus adding approximately 3Å for each residue 
to factor in protein dynamics.36 While BS3 and DSS are the simplest examples of 
homobifunctional crosslinkers, there are a myriad of heterobifunctional crosslinkers 
which can be useful to cover different distances or to target other side-chains.9 One other 
option to broaden the information obtained from crosslinking strategies is to use 
photoactive crosslinkers which are often significantly more promiscuous.  These 
crosslinkers contain aryl azides, diazirines, or benzophenones which react with numerous 
protein sites.9,37,38 Typically with this strategy the crosslinker is heterobifunctional, and 
one reactive functionality targets a specific site to allow the crosslinking to be anchored 
to the protein in a characteristic manner.   Then the partially modified protein is exposed 
to UV light to trigger the secondary reaction step. There is another class of crosslinkers 
which stitch together acidic residues (Asp, Glu, C-terminus)  by means of EDC (1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide) coupling to form a new peptide bond (Figure 
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1g).9 These crosslinks are called zero-length crosslinkers since there is no inserted length 
once the new peptide bond is formed. These reactions are ideal to determine spatially 
close residues or those that may be interacting.9 
While crosslinking experiments can provide a large wealth of information, the 
crosslinks are notoriously difficult to identify due to low reaction yields, and the 
fragmentation patterns of the crosslinked peptides are particularly difficult to interpret.   
The low reaction yields are due to the fact that during crosslinking reactions three 
reaction pathways may occur: no reaction, dead-end resulting from only a single reactive 
site with the other site hydrolyzing, and the successful crosslinking reaction. Upon 
digestion at least two different categories of crosslinked products may be detected:  intra-
peptide crosslinks and inter-peptide crosslinks.9,39 The successful crosslinking reaction 
occurs in low yield relative to no reaction at all or dead-end pathways. To attempt to 
overcome these drawbacks, tri-functional crosslinkers have been generated to allow 
enrichment of the crosslinks of interest (Figure 6a).40 These are either functionalized 
directly with a biotin group attached with a spacer arm for streptavidin enrichment,40 or 
they are functionalized in a  bio-orthogonal manner (such as click-chemistry) which can 
followed up with biotin attachment and crosslink enrichment.9 These strategies work well 
to reduce the overall complexity of the samples by removing unmodified peptides, but 
there still remains a mixture of dead-end and crosslinked peptides. Tri-functional 
crosslinkers also tend to be fairly bulky, in comparison to the bi-functional analogs, 
which can block access to reactive residues by steric factors.  
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Figure 6. Designer crosslinkers with homobifunctional attachment allowing (a) biotin 
enrichment and release through disulfide reduction and (b) CID specific 
fragmentation which is signified in red lines (DSSO).   
To attack the other main problem (overly  complex peptide fragmentation which 
confounds interpretation), another type of trifunctional crosslinker has been developed. 
Identifying the two crosslinked peptides is challenging because the total mass of the 
crosslinked product is comprised of two unknown peptides from different regions of the 
protein(s) plus the mass of the crosslinker.  Many peptide combinations might fit the 
mass of the crosslinked product.    Even with tandem mass spectrometry, the resulting 
fragments are difficult to assign to one specific chain of the peptide and not the other.39 
This problem can be partially resolved with the use of a high mass accuracy mass 
spectrometer to allow determination of a well-defined chemical composition of the 
crosslinked product. However, even high accuracy assignments fall short for more 
complexes mixtures of proteins that are subjected to crosslinking. In cases such as these, 
gas-phase specific fragmentation chemistry is embedded into the crosslinker, essentially 
via the incorporation of a cleavable bond in the crosslinker (Figure 6b).11,39 These 
crosslinkers are designed to undergo selective bond cleavage when subjected to 
collisional activation,  thus releasing the individual peptides that contribute to the overall 
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mass of the initial crosslinked product.11,39 Then MS3 can be used to sequence the 
constituent peptides.  This strategy also has the ability to distinguish between intra-
crosslinked and inter-crosslinked peptides and those with dead-end modifications. The 
most popular choice of gas-phase cleavable crosslinker is disuccinimidyl sulfoxide 
(DSSO) which fragments specifically at the neighboring bonds of the sulfoxide group.39  
1.2.3 Hydrogen-deuterium Exchange 
Hydrogen-deuterium exchange (HDX) is another form of covalent labeling; 
however, due to the nature of the experiment it is a completely reversible reaction.8,41 
This technique was born out of the classic HDX experiments performed with NMR.42 In 
HDX experiments proteins are exposed to high levels of deuterium oxide in solution. The 
amide hydrogen atoms of the protein backbone exchange as well as the side-chain 
hydrogen atoms on respective heteroatoms (N,S,O) with the deuterium atoms of  D2O.41,43 
The extent of deuteration per backbone position reveals the amount of protection or 
accessibility of the residue and its availability for exchange. The protected residues are 
either hydrogen-bonded to either the backbone or side chain or buried within the core of 
the protein. Those residues that appear unprotected (highly exchangeable) are in 
disordered regions or not involved in hydrogen bonds.44 HDX consistently gives the 
highest resolution structural information among all mass spectrometry labelling 
methods.43,45  
While this technique is superior to covalent labeling due to the high resolution 
structural information, there are some serious technical obstacles that must be overcome 
owing to the prevalence of back exchange once the protein is labelled with deuterium.41,43 
Side-chain exchanges are typically not observed in solution due to very rapid back-
exchange in solution upon contact with non-deuterated solvents, with the exception of 
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histidine.46 Briefly, the general workflow for a HDX experiment involves labeling the 
intact protein or proteins with deuterium oxide for a fixed amount of time followed by an 
acid quench and rapid freeze to discourage back exchange.41,45 The resulting mixture is 
then digested quickly by pepsin, a non-specific protease that is active at 0°C at pH 2. 
These attributes of pepsin are advantageous to obtained high percentages of overlapping 
sequence coverage and allow proteolysis to be performed at conditions that minimize 
back-exchange. The peptide mixture is separated over a reversed phase column with a 
fast gradient (typically under 15 minutes) to reduce peptide back exchange during 
chromatography.41,47 From the MS1 spectra collected, the extent of deuteration can be 
calculated by the isotopic mass shift of each peptide towards higher masses.44,45 MS2 
spectra are generally collected for peptide identification but not per residue deuterium 
content due to hydrogen scrambling by collisional activation methods.48,49  Interestingly, 
it has been recently shown that electron-based activation (such as electron transfer 
dissociation) of deuterium exchanged peptides and proteins does not cause an appreciable 
amount of hydrogen scrambling during fragmentation.50,51 The general HDX workflow 
described above, which was once a large technical challenge, has been commercialized 
by Waters Corporation and LEAP Technologies, allowing widespread adoption of this 
technique.  The commercial platforms offer automated sample handling including 
automation of exchange and the quenching, with additional automation for on-line pepsin 
digestion followed by injection onto the column that is cryogenically cooled to reduce 
back exchange during separation.  
HDX experiments are commonly collected over multiple time points for the HDX 
reaction; by using a broad range of HDX reaction times, a kinetic map of deuterium 
uptake into the protein backbone can be derived.43–45 HDX can also be applied in a pulsed 
type mode with a fixed time of labeling over the course of time of a reaction or during 
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folding/unfolding to probe specific protein conformational changes on a temporal 
dimension.45,52 An application of this is the study of conformational changes due to 
amyloid aggregation in solution over time, during which the amyloid aggregate size can 
be monitored by turbidity of the solution or dynamic light scattering experiments.52,53 
HDX has also been adopted heavily by the pharmaceutical industry for epitope mapping 
between antibody and antigen as well as comparing biosimilar drugs.45,54 Briefly, this is 
accomplished by measuring the exchange rates of the separate antibody and antigen and 
then monitoring the exchange rates upon their complexation. Those peptides that display 
a decrease in exchange rates are indicative of being involved in the epitope interaction. 
1.3 NATIVE MASS SPECTROMETRY 
Native mass spectrometry is the study of biological molecules sprayed and 
ionized from salt buffers in an attempt to mimic physiological solution conditions.55,56 
Unlike all the other mass spectrometry techniques discussed above, this technique does 
not involve protein digestion or labeling. Native mass spectrometry is a modified top-
down centric mass spectrometry technique in which intact proteins are analyzed by MS1 
and MS2 methods in an effort to derive stoichiometric and conformational insight. The 
goal of top-down mass spectrometry is to examine intact proteins without the need to 
reconstruct whole proteins from peptide pieces.57 Native mass spectrometry has the 
ability to build directly upon the advantages of top-down mass spectrometry to study 
intact proteins, protein-ligand complexes, and protein-protein complexes.55,56 
Changing solution conditions dramatically alters the resulting charge states of the 
protein.  In denaturing solvents, proteins are observed in a large range of high charge 
states , but proteins in native solutions generate a narrow range of low charge states 
(Figure 7).58  Typically denaturing solutions consist of >50% organic solvent with a low 
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percentage (<2%) acid component and no salts. Native solution are typically close to 
100% aqueous with a relative high concentration of a volatile salt:   ammonium acetate, 
ammonium bicarbonate, or ammonium formate in concentrations ranging from 5 mM to 
2 M depending on the ionic strength required to retain the protein interactions.  
 
Figure 7. Myoglobin sprayed under denaturing conditions in (a) 50% water:50% 
acetonitrile:0.1% formic acid. It can also be seen sprayed under native 
conditions in (b) 50 mM ammonium acetate at neutral pH. The heme group 
in retained during the native spray.  
These solvent changes are thought to alter the mechanism of ionization; protein ions from 
denaturing solutions follow the chain ejection model (CEM) whereas proteins from 
native solution experience the proposed charged residue model (CRM).58 The CEM 
suggests that the denatured protein unfolds, and the hydrophobic residues, which were 
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found in the interior region of the protein in the native state, arrange to the outer edge of 
the charged, hydrophobic droplets formed by the ESI process.58 Upon droplet shrinking 
owing to multiple coloumbic explosions, the hydrophobic portion of the protein will 
extrude itself through the barrier of the droplet and pick up surface charges resulting in 
the formation of highly charged protein ions. For the alternative CRM, the protein folds 
are retained and the protein remains near the center of the droplet.58 Upon continuous 
evaporation of the droplet, the charge from the surface of the droplet is deposited onto the 
surface of the protein, leading to a low number of charges on the protein.58 The narrow 
charge state distribution also provides support for the retention of a natively folded 
protein. While the mechanism of native spray and how native the gas phase structure is a 
hotly contested subject overall58–61, there is a growing amount of evidence supporting the 
premise that native-like protein structures are retained during the native spray process.62,63 
The other evidence includes retention of non-covalent interactions upon ionization34,64,65 
as well as collisional cross section measurements of the native protein charge states that 
align well with theoretical collisional cross sections based on solution models.66–68  
One of the common applications of native mass spectrometry is to monitor the 
stoichiometry and topology of large protein complexes.69 These range from the size of a 
hexamer comprised of two hetero-trimers (toyocamycin nitrile hydratase, 85.6 kDa) 70 to 
ATP-synthase (538 kDa) 71 to matured virus capsids (3-4 MDa).63 One general method for 
analysis of these large macromolecular complexes is use time of flight (TOF) mass 
spectrometry to measure the masses of the intact complexes.55,56,69 The resulting 
complexes can be mass selected and subjected to collisional activation to cause 
disassembly of the complex.69,71 This dissociates the complex into smaller subunit 
complexes, some which retain protein-protein interactions,  or ejection of monomer 
proteins from the complexes.69,71 Those smaller complexes generated by collisional 
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activation are indicative of protein-protein interactions within the larger complex. This 
information can be used to reconstruct the overall topology of the protein complex. A 
new alternative technique uses high energy collisions with a surface, surface induced 
dissociation (SID).72,73 With this technique the selected protein complex is accelerated 
into a large surface which offers fast activation and high energy deposition.73 SID has 
been shown to selectively break the weakest interface of the complex without unfolding 
the protein, an outcome that correlates with the total surface area of the protein interfaces 
and ultimately gives information about subunit structure (architecture).74 In contrast, 
conventional collisional activation of protein complexes proceeds by unfolding of a 
monomer subunit followed by ejection from the complex.70,74,75 An alternative approach 
to examining protein topologies by native mass spectrometry involves deliberate step-
wise disruption of the proteins complexes by addition of organic solvents to the 
solutions.76 In this experiment a gradient of organic solvent is added to the protein 
solution and the MS1 is repeatedly recorded. This method disassembles the complexes to 
reveal the  topology of the protein complex.76Topologies solved via this solution 
disruption method versus those cleaved by MS/MS methods in the gas phase have been 
shown to agree well.74,76  
Native mass spectrometry can be used to monitor protein-ligand interactions as 
well,62,64,65,77 a task that is very useful for screening protein-drug interactions78 and to 
optimize the use of lipids  for enhancing the analysis of membrane proteins.62,79,80 Some 
labs have been successful in using native mass spectrometry to measure dissociation 
constants of challenging protein systems.81–83 Very recently new methods have been 
developed to measure the thermodynamic binding constants of a series of membrane 
protein – lipid complexes.77 The study of protein-ligand interactions has also lead to 
understanding of biological mechanisms. For example, the mechanism of an ABC 
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transporter (TmrAB) that was unclear by crystallographic methods was proven by native 
mass spectrometry experiments.80 It was determined that this ABC transporter needed 
dual ATP binding and hydrolysis to transport lipid-A type molecules across the 
membrane.80 
Another avenue for studying protein-ligand interactions by native mass 
spectrometry involves the use of high energy and/or electron activation (as opposed to 
low energy collisional activation) techniques to localize the binding sites.75 High energy 
or electron activation of a protein ligand complex can cause covalent bond cleavage 
while retaining non-covalent protein-ligand interactions that are confirmed based on 
observation of fragment ions that retain the ligand even when the backbone of the protein 
has been cleaved.64,65,84–88 These ligand-retaining fragments are referred to as holo 
fragments. Three specific high energy or electron-based activation techniques that exhibit 
this phenomenon are electron-capture dissociation (ECD), its non FT-ICR analog 
electron transfer dissociation (ETD), and ultraviolet photodissociation (UVPD).  Briefly, 
ECD uses high energy electrons from a heated filament to interact with the ion of interest, 
such as proteins.89,90 This activation method yields mainly c/z type fragments ions.  ETD 
entails the transfer of an electron from a fluoranthene anion to the positively charges ion, 
also resulting in product ion of c/z ions.91  In the UVPD process, an ion may absorb 
photons from a laser, ultimately resulting in fast, high energy activation that generates 
a/b/c and the x/y/z type ions with unprecedented sequence coverage for top-down 
analysis.92,93 With each of these techniques yielding holo fragments, it is possible to 
reconstruct the site of non-covalent interactions between the protein and the ligand of 
interest.64,85,87,94 UVPD in particular is the subject of much of the research in the present 
dissertation.  
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In addition to using these activation techniques in conjunction with native mass 
spectrometry to localize ligand binding, it has also been shown that these fast high energy 
activation techniques can be used to study conformational changes of proteins.94–96 
Conformational changes of proteins can originate from ligand binding, amino acid 
substitutions, or changing initial solvent conditions. Additionally, ETD has been recently 
shown to be a valuable tool to determine salt bridges in the gas phase.97 
1.4 OVERVIEW OF CHAPTERS 
Despite the versatility and impressive capabilities of the various mass 
spectrometry methods summarized above for the characterization of biological 
macromolecules, there remains room for many more advances in the technologies and 
applications.  This dissertation will focus on the development and applications of 
nativespray mass spectrometry for an array of structural biology problems. Chapter 3 will 
demonstrate the adaptation of crosslinking to a top-down type platform in contrast to the 
commonly used bottom-up type platform. The impetus for this work is to characterize 
complexes via a top-down approach to offer a more powerful means to pinpoint 
crosslinks.  This top-down approach should also be well-suited for examination of 
crosslinks in proteins that contain post-translational modifications, ones that might be 
missed using bottom-up methods for which complete sequence coverage is rarely 
attained.   
The remainder of the dissertation focuses on using native-MS UVPD 
methodology to probe protein-ligand complexes, particularly to characterize the locations 
of bound ligands (co-factors or inhibitors) and to map conformational changes that arise 
from ligand binding.  The complex loop rearrangements of dihhydrofolate reductase 
(DHFR) during its catalytic cycle, which results in the conversion of dihydrofolate to 
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tetrahydrofolate, have been studied extensively using conventional methods such as 
NMR and X-ray crystallography.98,99 Thus, DHFR serves as an excellent benchmark 
system to explore the use of UVPD to monitor conformational changes upon binding of 
the co-factor (NADPH), the substrate (DHF) and an inhibitor (MTX), as described in 
Chapter 4.  The capabilities of UVPD-MS to characterize conformational changes as a 
function of point mutations and the impact of inhibitor binding is expanded for DHFR 
and two clinically isolated mutants in Chapter 5.  This study focused on DHFR variants 
from Escherichia coli which have exhibited resistance to  trimethoprim.  This study 
entailed a multi-prong approach that utilized nativespray MS and UVPD, size exclusion 
chromatography, and measurement of Michaelis-Menten kinetics and inhibitory kinetics 
by spectrophotometry. Results showed that the two mutants, P21L and W30R, resisted 
inhibition by TMP through two separate mechanisms. Whereas the W30R mutant relied 
on a reordering of the substrate-binding pocket for steric resistance, the rigidity of the 
M20 active loop was modulated for the P21L variant which allowed facile exchange 
between the substrate and TMP while retaining the substrate binding pocket structure.  
In the final chapter, UVPD-MS was used to characterize the conformation of the 
Kirsten rat sarcoma (K-Ras) viral oncogene homolog and two single point mutations. K-
Ras performs GTP hydrolysis in the cell upon interaction with its effectors in the cell. 
Mutations of K-Ras are very common in a wide range of cancers. These mutations 
impede the interaction with said effectors which in turn leaves K-Ras in the activated 
state with GTP bound. This leads to elevated GTP levels in the cell signaling for cell 
proliferation and downstream signaling. It was found that the structural dynamics or 
conformations changed significantly in their function with respect to the type of amino 
acid substitution at the Gly12 position in the K-Ras protein. These observations suggest 
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that specific G12X mutations may induce mutation-specific down-stream interactions 
driving cancer growth.  
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Chapter 2:  Experimental 
 
2.1 ORBITRAP MASS SPECTROMETER 
A Thermo Orbitrap Velos Elite mass spectrometer was used for all analysis 
involving UVPD fragmentation. It has been modified for UVPD in the HCD cell as 
previously described in Shaw et al.1  A schematic representation with labelled sections of 
the Orbitrap mass spectrometer are shown in Figure 1. The first section depicts the ESI 
source which generates ionized proteins which enter the heated capillary for further 
desolvation. After desolvation the ions are direct through ion optic multipoles to the dual 
pressure linear ion trap (section 3).  
 
Figure 1. Schematic representation of Thermo Scientific Instruments Orbitrap Elite mass 
spectrometer illustrating the six main sections described in the text.  The 
sections include:  1) ESI source,  2) ion optics,  3) dual pressure linear ion 
traps,  4) C-trap,  5) HCD cell where UVPD is implemented, 6) Orbitrap 
mass analyzer.  
The dual pressure linear ion trap is responsible for low resolution mass detection as well 
as performing collisional activation and is also the section of the instrument that is 
capable of performing ETD and ion isolation. From here intact ions or those generated 
from fragmentation that require high resolution analysis are passed to section 4 of the 
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instrument deemed the C-trap. The C-trap is responsible for collecting the ions before 
injection into the orbitrap (section 6) for high resolution detection. Ions can also be 
fragmented with beam type collisional activation in the HCD cell (section 7). The HCD 
cell is also where UVPD occurs by irradiation of ions using a 193 nm Coherent excimer 
laser.  Orbitrap detection generally allows intact proteins or fragments of proteins to be 
detected from m/z 200-4000 with resolution of 120k to 240k at 400 m/z. The orbitrap is a 
high accuracy detector yielding sub 10 ppm error tolerances for mass detection.  
 
 
2.2 PROTEIN CROSSLINKING EXPERIMENTATION 
2.2.1 Crosslinking Reactions 
Crosslinking reactions are used to covalently link two reactive and accessible 
amino acids between two separate interacting proteins or within a single protein itself. 
Experiments such as these reveal spatial information about the protein interactions or the 
nearness of particular residues in one protein based on the crosslink distance constraints. 
Many different reactive crosslinking chemistries have been developed and are employed 
to study a wide array of protein interactions. Crosslinkers can also be synthesized with 
varying spanning lengths to discriminate between short and long range interactions. 
Bovine ubiquitin and bovine insulin were prepared in a 1X PBS buffer prior to 
labeling with the homobifunctional crosslinker bis(sulfosuccinimidyl)suberate (BS3) 
(Figure 2). Zinc acetate was added as well for the insulin sample to induce hexamer 
formation. Proteins were reacted at a 1:10 ratio with BS3 (protein:BS3) (Figure 2) for 10 
minutes to avoid excessive crosslinking. Samples were quenched by addition of 0.1% 
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formic acid. Excess BS3 was removed by passing the solution through a 3 kDa molecular 
weight cut-off filter. 
 
Figure 2. BS3 (bis(sulfosuccinimidyl)suberate) crosslinker 
2.2.2 Reversed-Phase Liquid Chromatography 
A Dionex nano-LC system was equipped with a 5 cm trapping column and a 30 
cm analytical column each packed in house with polymeric reversed phase media (PLRP-
S) at a 5µM particle size. The column had a 360 µM outer diameter with a 75 µM inner 
diameter. The trap was washed at 5 µL/min with loading solvent, composed of 98% 
water, 2% acetonitrile and 0.1% formic acid, after sample loading for a minimum of 6 
minutes, then the trap column and analytical were aligned by a valve switch and the 
mixture of crosslinked proteins were separated at 400 nl/min. The solvent system used 
contained 0.1% formic acid in water (solvent A) or 0.1 % formic acid  in acetonitrile 
(solvent B). Proteins were eluted over a gradient of 30 minutes from 20% to 40% solvent 
B. 100 ng of protein material was typically injected for each experiment. The nanoLC 
system was interfaced to an Orbitrap Elite mass spectrometer that was equipped with a 
193 nm laser for UVPD. A 2kV potential was applied at the tip of the column to induce 
nanospray.  
2.2.3 Targeted MS/MS Fragmentation 
Targeted UVPD and HCD runs were performed on the singly intra-protein 
crosslink for ubiquitin and the singly inter-protein crosslinked insulin. For ubiquitin the 
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7+ species (m/z 1243.68) was targeted. For insulin the 8+ species (m/z of 1451.42) was 
targeted. All MS2 spectra were collected at 120,000 resolution at 400 m/z. A single 3 mJ 
pulse from the 193 nm laser was used for UVPD, and 31% NCE was applied for HCD 
fragmentation.  20-50 scans were averaged per MS/MS spectrum. 
2.2.4 Data Analysis 
MS2 scans were averaged across the most abundant and well-resolved peaks with 
Gaussian shape in comparison to the baseline.  The spectra were deconvoluted by using 
Thermo Xtract with a S/N threshold of 3. The produced monoistopic peak list was 
analyzed with ProSight Lite, a database search algorithm and top-down data analysis 
algorithm originally developed in the Kelleher lab. For each decharged spectrum of 
ubiquitin, two separate searches were performed, one to identify the unmodified 
fragments, and the second to identify sites of crosslinking. The second was searched by 
adding +138. 069 Da (the mass addition of the crosslinker) to each termini to identify 
fragment ions that were covalently crosslinked. The sequence offset of the unmodified 
series of fragments and the onset of the modified fragments indicated the sites of 
crosslinking. The data was searched similarly for crosslinked insulin, but instead the 
summed mass of insulin plus the BS3 mass was added at all possible sites of crosslinking 
on the insulin A and B chains. There was one possible site on the A chain at the N-
terminus and two sites on the B chain at the N-terminus and K29 (or KB). As with 
ubiquitin the resulting series of unmodified and modified fragments indicated the sites of 
crosslinking within insulin dimers.  Note that the crosslinked dimers were produced from 
a hexameric form of insulin in solution. 
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2.3 NATIVE MASS SPECTROMETRY OF PROTEINS 
Native mass spectrometry of proteins uses non-denaturing conditions in contrast 
to standard denaturing ESI used for protein analysis. These conditions are most 
dependent upon using volatile salt buffers such as ammonium acetate or ammonium 
bicarbonate at biologically relevant pH. This is in contrast to typical denaturing protein 
ESI which the solvent is composed of greater than 50% organic solvent (methanol or 
acetonitrile) with the addition of low percentages of acetic or formic acid. When 
applicable a static tip emitter spray is used instead of an ESI source. This allows the 
application of very low voltages (0.8 – 2kV) for protein ionization in comparison to 
standard ESI (3-4kV). Using substantially lower voltages in turn lowers the internal 
energy of ions based on the heat generated in the resulting droplet produced either by ESI 
or through a static tip setup. It is also typical to lower the heated capillary temperature 
from 300°C (for denaturing ESI) to a range between 50°C to 200°C for native 
experiments. The overall goal of spraying a native protein is to keep the internal energy 
of the gaseous protein as low as possible while it travels into and through the mass 
spectrometer by adjusting said parameters above. This low energy approach is done at the 
expense of sensitivity.  
2.3.1 Mass Spectrometry 
All native mass spectrometry experiments were undertaken using an Orbitrap 
Elite mass spectrometer which was interfaced to a 193 nm excimer laser for UVPD. All 
experiments using native mass spectrometry were performed by static spray using an 
offline nanoESI kit to modify the existing nanoESI source.  This nanoESI kit consisted of 
a ring electrode to hold and apply voltage to the coated tips along with the ability to apply 
backpressure to the static tip during ionization. 1.2 mm outer diameter borosilicate 
capillaries were pulled to fashion 20-50 µM inner diameter  tips, then coated to 20 nm 
 30 
thickness uniformly on the capillary surface with a gold:palladium (20:80) mixture.  
These coated borosilicate capillaries were used for all nativespray experiments.  In this 
fashion the ring electrode from the offline nanoESI source came in contact with the metal 
on the tip and induced an electroosmotic current which caused the sample to flow and 
resulted in production of a spray. Spray voltages between 0.8 to 2.0 kV were used for 
spraying the proteins. All proteins were sprayed out of varying concentrations of 
ammonium acetate solvent and pH values. K-Ras proteins were specifically sprayed out 
of 50 mM ammonium acetate at pH 7.8 to facilitate full co-factor binding (Chapter 6). 
DHFR proteins were sprayed out of 50 mM ammonium acetate at pH 6.5 in Chapter 4 
and 150 mM ammonium acetate at pH 6.5 with 2% DMSO to facilitate anti-folate 
solubility in solution in Chapter 5. The temperature of the heated capillary (a component 
of the ESI interface that facilitated desolvation of ions) remained between 100 – 200°C 
for all native experiments. MS2 of each protein was performed using a single 3 mJ pulse 
of the 193 nm laser.  MS/MS spectra were acquired at a resolution of 120k at 400 m/z, 
and up to 250 scans were averaged for DHFR experiments, and a resolution of 240k at 
400 m/z and up to 750-1000 scans were averaged for K-Ras experiments. The laser power 
was adjusted for DHFR analysis in Chapter 5 to 2.5 mJ. For the acquisition of UVPD 
mass spectra, the Orbitrap was scanned from m/z 220 to 4000 with a standard 10 mTorr 
pressure in the HCD cell.  
2.3.2 Size Exclusion Chromatography – Native MS 
SEC experiments were performed on a Dionex LC system interfaced with a 
Thermo Velos Pro dual cell ion trap mass spectrometer. The LC was interfaced with the 
mass spectrometer using a HESI source. The HESI source differs from the nanoESI 
source in that typical spray voltages range from 3-4kV and nitrogen sweep gas and 
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nitrogen auxiliary gas can be used to improve desolvation. A HESI source is used for 
capillary to analytical flow experiments. The Dionex LC was set up in a direct injection 
fashion bypassing any preconcentration steps. In short the loading pump was plumbed 
through the autosampler and then directly to the entrance of the column and then attached 
directly to the HESI source. A 4 kV voltage was applied at the source to facilitate ESI. A 
2.1 mm x 30 cm Zenix-C column with an 80 Å pore size (80,000 MW exclusion limit, 
protein MW range 100-80,000 Da) and 3 µm particle size from Sepax Technologies was 
employed for SEC separation. The stationary phase was hydrophilic film bonded silica. 
The mobile phase for all SEC experiments was 150 mM ammonium acetate at pH 6.5 
which flowed at 80 µL/min. Each protein solution was composed of 12 µM DHFR with 
excess ligands in 150 mM ammonium acetate with 2% DMSO. 5 µg of protein was 
injected for each experiment (which corresponded to an injection volume of 20 uL of the 
aforementioned solution). The mass spectrometer was set to scan from m/z 1500-4000 
and a small 10 m/z window centered around the expected ligand(s) m/z in an alternating 
fashion to allow monitoring the protein complexes and free ligands.   
2.3.3 Data Analysis 
All collected UVPD mass spectra were deconvoluted to monoisotopic masses by 
using Xtract with a S/N of 2 to 3 prior to data analysis. Chapters 4 and 6 used Prosight 
PC 3.0, from the Kelleher lab, that was modified to accompany searching UVPD type 
ions (a, a•, b, c, x, x•, y, y-1, and z). Chapter 5 involved the use of a fragment 
identification algorithm developed in-house by Jake Rosenberg. The in-house algorithm 
produced a list of identified ions with their respective intensities. It also allowed facile 
summation of ion intensities over the entire backbone as well as allowed this information 
to be split into summed ion intensities arising from the N versus C terminus. 
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Additionally, the algorithm offered the ability to search for numerous mass shifts induced 
by ligand binding. These two described utilities of automatic ion summation and mass 
shifts due to ligand binding are not available with the current commercially available top 
down software (Prosight PC 3.0). In general two types of searches were performed for 
each protein-ligand complex. The first revealed the ion abundances of apo (ligand free) 
fragment ions. The second revealed the holo (ligand-containing) fragment ion 
abundances by searching all fragment ions again while including the expected mass of 
the ligated small molecules added on both the N- and C-termini of the protein. To 
normalize, the abundances of the identified fragment ions were divided by the total ion 
current of the recorded mass spectra. The N- and C-terminal ions were then summed in a 
complementary fashion across the backbone from the N terminus to C terminus. For 
example, N-terminal ions with fragment position n (an, bn, cn) are summed with C-
terminal ions with fragment position n or (xR-n+1, yR-n+1, zR-n+1) where R is total number of 
residues in the protein. (Figure 3) These two series of ions (apo and holo) were then 
summed together to generate the total fragment ion abundance across the protein 
backbone. 
 
Figure 3. Pictorial description of summing N and C terminal ion intensities per amino 
acid residue.  
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Chapter 3:  Structural Characterization of Intra- and Intermolecular 




Interactions within and between proteins impact structure and function, and 
mapping these interactions is a key hallmark of structural proteomics. One popular 
method for mapping protein interactions utilizes homobifunctional crosslinkers with 
defined distance constraints, followed by bottom-up mass spectrometry analysis. In this 
study, characterization of protein crosslinks was accomplished by top-down mass 
spectrometry (MS) using both ultraviolet photodissociation (UVPD) and higher energy 
collisional dissociation (HCD) in conjunction with reversed phase nanoscale liquid 
chromatography (nanoLC). Four intramolecular crosslinks of ubiquitin were identified, 
all in agreement with the known tertiary structure. Three intermolecular crosslinks of 
insulin were unambiguously assigned, consistent with the hexameric complex adopted by 
insulin in solution. This integrated top-down nanoLC/UVPD/HCD-MS approach affords 
a powerful strategy for deciphering details about tertiary structure and intermolecular 
protein interactions. 
3.2 INTRODUCTION 
Chemical crosslinking of proteins and protein complexes followed by proteolysis 
and analysis of the crosslinked peptides by conventional bottom-up mass spectrometry 
workflows has proven to be an exceptionally powerful strategy for providing key insight 
into protein conformations, protein interfaces, and protein interactomics.1 However, by 
their very nature bottom-up methods create very complicated mixtures, ones in which 
low abundance cross-linked peptides might be missed, and each crosslinked peptide 
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provides at most one contact point. A compelling alternative is a top-down approach in 
which intact proteins (or protein complexes) are analyzed to provide a more holistic 
perspective for deciphering protein interactions.2,3 Recent developments of new ion 
activation techniques4,5 and ongoing improvements of high resolution instrumentation6 
have advanced the field of top-down mass spectrometry to allow greater sequence 
coverage of individual proteins7 and grander scale mapping of the whole proteome.8 In 
terms of top-down strategies for crosslinked proteins, only two studies have been 
reported,9,10 both focusing on characterization of ubiquitin crosslinked in solution or in 
the gas phase, respectively, by homobifunctional amine-specific N-hydroxysuccinimide 
ester-type linkers. Each study used collisional activated dissociation for characterization 
of the crosslinked ubiquitin, and each found two crosslinks, K6 to K11 and K48 to K639 
or K27 to K29 and K48 to K63,10 respectively. The studies in which crosslinking was 
combined with top-down MS/MS analysis are over a decade old9,10 and have not been 
surpassed with newer findings, thus attesting to the challenges of top-down approaches 
for examination of crosslinked proteins. The primary limitations are apparent: sub-par 
sequence coverage from conventional collisional activation which restricts confident 
localization of crosslinks, as well as the difficulty of deriving site-specific information 
from heterogeneous populations of crosslinked proteins. We have addressed these hurdles 
by employing both ultraviolet photodissociation (UVPD) and higher energy collisional 
dissociation (HCD) to provide an unprecedented level of sequence coverage in 
conjunction with nanoscale liquid chromatography (nanoLC) to separate the crosslinked 
proteins, ultimately allowing unambiguous identification of the crosslinks. This strategy 




3.3.1 Crosslinking of Ubiquitin and Insulin 
Bovine ubiquitin (50 µM) or bovine insulin (15 µM) were prepared in 1X PBS 
buffer, the latter with additional zinc acetate added to five times the insulin concentration 
to promote formation of the active insulin hexamer. Each solution was reacted with 
bis(sulfosuccinimidyl)suberate) (BS3) at a 1:10 (protein:BS3) molar ratio for 10 minutes, 
then subsequently quenched via addition of approximately 5 µL of 0.5% formic acid. The 
protein:BS3 ratio and reaction time were kept low to minimize formation of multiple 
crosslinks per protein, an outcome that confounds top-down MS/MS spectra 
interpretation. Excess BS3 was removed by passing each solution through a 3 kDa 
molecular weight cut-off filter. 
3.3.2 Mass Spectrometry and Liquid Chromatography 
100 ng of protein material was injected on a nanoLC system equipped with a 5 cm 
loading polymeric reverse phase media (PLRP-S) column at 5 uL/min prior to a 30 cm 
PLRP-S column at 400 nl/min with 0.1% formic acid in water (A) and acetonitrile (B) for 
mobile phases. The nanoLC system was interfaced to a Thermo Scientific Orbitrap Elite 
mass spectrometer modified for UVPD in the HCD cell, as described previously.(7) The 
electrospray voltage was held at 1.8 kV, and the mass spectrometer was set to target 
intramolecular crosslinked ubiquitin (Mr 8697.68 Da, target m/z 1244.39 (7+)) or 
intermolecular crosslinked insulin (Mr 11597.29 Da, target m/z 1451.52 (8+)). The 
collision energy for HCD was set to NCE 31%. A single 3 mJ laser pulse was used for 
UVPD. All MS2 spectra were collected at 120 K resolution at m/z 400 averaging 5 
µscans. 
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3.3.3 Data Analysis 
MS/MS spectra were deconvolved using Xtract with a S/N ratio of 3. The 
resulting deconvoluted mass spectra were searched using ProSight Lite both with and 
without the crosslinking mass shift (+138.069 Da) fixed on either termini to determine 
sites of crosslinker attachment with a 6 ppm mass error tolerance. Inter-protein crosslinks 
for insulin were searched by fixing the mass of an insulin monomer plus the mass of the 
crosslinker (Mr 5867.69 Da) to the N-terminus of the A and B chains of insulin as well as 
K29 on the B chain.  
3.4 RESULTS AND DISCUSSION 
3.4.1 Ubiquitin Crosslinks 
The chromatographic profiles obtained for the BS3-crosslinked ubiquitin mixture 
are shown in Figure 1a with the unmodified, dead-end (i.e. hanging linker with one end 
hydrolysed, +156.083 Da), and crosslinked (+138.068 Da) species color-coded based on 
the extracted ion chromatograms for the 7+ species of each. Each type of product was 
successfully separated, and isomeric crosslinked species appeared as distinctive 
chromatographic peaks. Examination of the charge state distributions of each product 
type (shown in the inset of Figure 1a) revealed a decrease in average charge state going 
from unmodified ubiquitin to the dead-end product to the crosslinked species.  This trend 
paralleled the number of basic sites;  BS3 reacts with primary amines, converting them to 
less basic sites. Each of the crosslinked products was characterized by UVPD and HCD. 
The resulting MS/MS spectra for the 7+ charge states are shown in Figure 2, and the 
corresponding fragmentation maps are shown in Figure 3. Crosslinks were determined 
by locating the transition from unmodified fragment ions to fragments containing a mass 
shift corresponding to the crosslinker mass. The primary amines (lysine side-chain or N-
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termini) closest to each transition were considered to be the sites that were crosslinked 
unless otherwise stated.  
 
Figure 1. Chromatographic profile for a) crosslinked ubiquitin and b) hexameric insulin 
showing the total ion chromatographic trace (black) and extracted ion 
chromatograms for unmodified (red), dead-end (green) and crosslinked 
(blue) proteins. ESI-mass spectra from each species (middle)  and expanded 
regions (far right, normalized and overlaid on a single m/z axis) of the mass 
spectra are shown next to the chromatographic profiles. 
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Figure 2. UVPD (a-d) and HCD (e-h) spectra of each crosslink of ubiquitin based on 
activation of the 7+ charge state. UVPD was performed using 1 pulse of 3 
mJ, and 31% NCE was used for HCD. 
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Figure 3. Fragmentation maps (as designated by slash marks along the backbone) for 
UVPD (all on left) and HCD (all on right) for each crosslinked species of 
ubiquitin. For each of the four crosslinked species, a pair of fragmentation 
maps is shown, with the upper one representing unmodified fragment ions 
that don’t contain the crosslink mass shift and the lower one reflecting 
fragment ions containing the crosslink mass shift (+138.0686 Da).  For the 
lower maps in each pairing, the N-term and C-term residues are shaded 
orange to indicate that the crosslink mass shift was added to all N-term and 
C-term fragment ions during the searches. Yellow-shaded boxes outlined in 
blue indicate the sites of the crosslinks. Black boxes around some of the 
residues are non-informative and an artifact of the ProSight Lite display. 
Analysis of the UVPD fragmentation patterns revealed three crosslinked species 
in which the following pairs of sites were linked by BS3:  K11 to K33 (tr 34.3 min), N-
terminus to K29 (tr 35.6 min) , and N-terminus to K63 (tr 37.2 min). Analysis of the 
complementary HCD spectra indicated that the first eluting crosslinked species was 
comprised of two products (Figure 4a, red and green extracted ion chromatograms). The 
second co-eluting crosslinked product (tr 34.6 min) was identified by the appearance of 
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an unmodified y58 fragment ion (m/z 1306.506, 5+ charge state), suggesting a crosslink 
between K6 and K11.  
 
Figure 4. Extracted ion chromatograms (XIC) of the identified crosslinks in: a) ubiquitin 
(expanded chromatographic profile (t = 34 to 38 min) from Figure 1a) and 
b) hexameric insulin (expanded chromatographic profile (t = 27 to 31 min) 
from Figure 1b). Four intramolecular crosslinks were identified for ubiquitin 
and are shown as color coded bars in the NMR structure (PDB: 1D3Z) that 
match the colors of the XICs. Ions used for XIC of ubiquitin were m/z 
1407.6 (y74 + xlink), 1307.3 (y58), 1735.5 (b30 + xlink), and 1683.9 (internal 
fragment) for the red, green, blue and orange traces, respectively. Three 
intermolecular crosslinks were identified for hexameric insulin and are 
shown as color coded bars in the NMR structure (PDB: 1AI0) with a view 
of the top and side of the hexamer. The ions used for XIC were m/z 1475.18 
(A-chain, a1 + xlink + insulin), 526.28 (A-chain, b5), and 1237.9 (B-chain, y3 
+ xlink + insulin) for the red, green and blue traces, respectively.  
Closer inspection of the extracted fragment ion abundances across the elution 
profile of the first crosslinked peak (tr 34.2-34.9 min) showed a demarcation among some 
of the fragment ion abundances, with a unique series of fragment ions occurring for the 
later-eluting species (green trace) suggesting a second isomeric crosslinked form (see 
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Figure 5). UVPD and HCD proved to be complementary because the N-terminus to K29 
crosslink could not be confidently identified from the HCD fragmentation map, and the 
second crosslinked product (K6 to K11) was obscured in the richer UVPD fragmentation 
map.  
 
Figure 5. Overlay of backbone cleavage maps generated upon HCD of crosslinked 
ubiquitin (tr 34.3 min) in which all N-terminal and C-terminal product ions 
attributed to cleavage at each backbone position are summed. The red traces 
are from peak 1a while the green traces are from peak 1b. These correspond 
to the traces in Figure 2 for the first co-eluting crosslinked species.  
All crosslinks identified based on the UVPD and HCD spectra fell within the 
distance constraint of BS3 (maximum 24.2 Å spatial distance between Cα of each linked 
residue). Additionally, the extracted ion chromatographic profiles in Figure 4 facilitated 
comparison of the relative abundances of the crosslinked products. The N-term to K63 
crosslink was the most abundant and thus was considered the dominant crosslink formed. 
Interestingly, this particular crosslink cannot be successfully identified without 
chromatographic separation due to the convolution of fragment ions arising from 
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isomeric crosslinked species which prevents localization of the crosslink site. The 
expected K48 to K63 crosslinked product was not identified in the present study; 
apparently its low abundance prohibited detection and perhaps was due to inefficient 
reaction at K48 or insufficient chromatographic resolution to separate this crosslink and 
alleviate ionization suppression from other more abundant co-eluting products. 
Comparison of the number of diagnostic fragment ions generated by UVPD and HCD 
(Figure 6) indicated that UVPD generated significantly more fragment ions per 
crosslinked species, including both unmodified fragments (i.e. fragments that did not 
contain the crosslink) as well as fragments that incorporated the crosslink.  
 
Figure 6. Fragment identifications per crosslink identification for UVPD and HCD based 
on searching for both unmodified and crosslinked fragments.  
Interestingly, HCD produced a smaller portion of fragment ions that contained the 
crosslink and instead favored formation of unmodified fragment ions (N-terminal and C-
terminal fragments from either side of the crosslinked segment). The identification of 
crosslinked sites provides spatial constraint information but does not allow construction 
of complete three dimensional structures.  
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3.4.2 Insulin Crosslinks 
A similar story emerges for the crosslinks identified upon analysis of hexameric 
insulin (e.g. a trimer of dimers). Briefly, first the 5+ charge state of intact monomeric 
insulin (Mr 5729.62 Da) was characterized by UVPD and HCD to evaluate sequence 
coverages for a heavily disulfide-bound protein (Figure 7).  
 
Figure 7. Fragmentation maps for both chains of intact monomeric insulin from (a) 
UVPD and (b) HCD. Each map represents a variation of the A chain or B 
chain depending on which disulfide bonds are cleaved. Grey-shaded 
cysteines indicate hydrogen losses to compensate for disulfide bonds formed 
in solution. Orange-shaded cysteines indicate addition of either the A chain 
(+2333.94 Da) or B chain (+3395.65 Da) of insulin with respect to the B or 
A chain, respectively. Black boxes around some of the residues are non-
informative and an artifact of the Prosight Lite display. 
UVPD gives extensive sequence coverage well beyond the disulfide-bound sections in 
comparison to the rather scanty interior fragmentation seen with HCD. Insulin forms 
hexameric complexes when in solution with zinc ions (Figure 8). After incubation of 
insulin with BS3, the resulting chromatographic profile highlighting unmodified 
monomeric insulin (4+), dead-end modified monomeric insulin (4+), and crosslinked 
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insulin (8+) is shown in Figure 1b. Each molecule of insulin has three primary amines: 
the N-terminus of the A chain (NA), the N-terminus of the B chain (NB), and Lys29 of 
the B chain (KB).   
 
Figure 8. Nativespray mass spectra of hexameric insulin acquired (a) in the ion trap and 
(b) in the Orbitrap (240 k resolution at m/z 400. A 1.5 kV was applied to the 
tip.  The solution contained  10 0mM ammonium acetate, 20 µM Zn acetate, 
and 10 µM bovine insulin. The monomeric (M) and hexameric (H) species 
the dominant species; there is some pentamer (P) present as well. Dimers are 
not observed.  
This set of reactive sites affords up to six theoretical crosslink sites for any pair of insulin 
molecules, all within the expected 30 Å distance constraint of BS3.(11) Intermolecular 
crosslinks were elucidated by careful inspection of fragment ions bracketing the three 
possible sites of crosslinking (NA, NB, KB) based on the extensive UVPD 
fragmentation. As with ubiquitin, targeted UVPD and HCD were performed on the 
intermolecular crosslinked species of insulin (Mr 11597.29 Da, target m/z 1451.52 (8+)), 
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revealing two major species and one minor species (Figure 4b) via extracted fragment 
ion profiles. The first eluting product was crosslinked between NA and NB of two insulin 
molecules based on the fragmentation pattern from UVPD (Figure 9, 10, and 11).  
 
Figure 9. UVPD (a-c) and HCD (d-f) spectra of each of the three intermolecular 
crosslinked insulin forms based on activation of the 8+ charge state. UVPD 
was performed using 1 pulse of 3 mJ, and 31% NCE was used for HCD. 
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Figure 10. Fragmentation maps for both chains of insulin obtained by UVPD. Grey-
shaded cysteines indicate hydrogen loss modifications to accommodate for 
disulfide bonds. Orange-shaded cysteines indicate addition of either the A 
(+2333.94 Da) or B (+3395.65 Da) chain of insulin with respect to the B or 
A chain, respectively. Crosslink modifications were searched at the N-
terminus of the B chain (Phe residue) or K29 of the B chain as well as at the 
N-terminus of the A chain (Gly residue) with the addition of +5867.66 Da 
(corresponding to insulin + crosslinker mass). Yellow-shaded boxes 
outlined in blue indicate the sites of the crosslinks. There is only one yellow 




Figure 11. Number of fragment ions identified per search for each intermolecular 
crosslink species from hexameric insulin based on UVPD and HCD with 
respect to each chain of the protein. A1-3 or B1-3 indicate the chain as well 
as the specific LC peak from which the fragment identifications correspond. 
Peaks 1-3 correspond to NAxNB, NBxNB, and NAxKB, respectively.  +B 
chain or +A chain indicate the addition of the mass of the A or B chain, 
respectively, to the indicated cysteine in Supplemental Figures 8 or 10.  The 
addition of the crosslinked insulin mass is signified by +insulin at each point 
of possible attachment which include the N-terminus of both the A and B 
chains as well as the B chain lysine.  
This crosslink assignment was confirmed by identification of fragment ions that matched 
N- or C-terminal sequence ions containing a mass shift corresponding to addition of one 
molecule of insulin plus the crosslinker (+5876.662 Da mass shift). For the second 
eluting crosslink species (NBxNB), there were few fragments ions that contained the 
modification on the N-terminus of the A chain, and there were a number that contained 
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the modification of the N-terminus of the B chain. The third eluting crosslink species was 
a minor product crosslinked between NA and KB based on the identification of many 
new crosslink-modified C-terminal ions from the B-chain and crosslink-modified N-
terminal A-chain ions not observed previously. Additional crosslinked fragment ions 
related to the N-terminus of the B chain were due to chromatographic overlap from the 
second crosslinked product and thus were not diagnostic for the NAxKB crosslink. For 
crosslinked insulin, HCD did not provide any additional information nor did it contradict 
the assignments based on the UVPD spectra (Figure 12). 
 
Figure 12. Fragmentation maps for both chains of insulin obtained by HCD. Grey-shaded 
cysteines indicate hydrogen loss modifications to accommodate for disulfide 
bonds. Orange-shaded cysteines indicate addition of either the A (+2333.94 
Da) or B (+3395.65 Da) chain of insulin with respect to the B or A chain, 
respectively. Crosslink modifications were searched at the N-terminus of the 
B chain (Phe residue) or K29 of the B chain as well as at the N-terminus of 
the A chain (Gly residue) with the addition of +5867.66 Da (corresponding 
to insulin + crosslinker mass). Yellow-shaded boxes outlined in blue 
indicate the sites of the crosslinks. There is only one yellow box in NBxNB. 
Black boxes are uninformative and are part of Prosight Lite display.  
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3.5 CONCLUSION 
 We have demonstrated the ability to confidently characterize both 
intramolecular and intermolecular protein crosslinks by using a powerful top-down 
strategy that combined nanoLC with two complementary activation methods, HCD and 
UVPD. Identification of several minor and predominant crosslinked products was 
accomplished based on examination of chromatographic peak profiles and extensive 
sequence maps. The construction of extracted ion chromatographic profiles generated 
from structure-specific fragment ions allowed co-eluting crosslinked products to be 
resolved and characterized individually, a significant advantage given the complexity of 
fragmentation patterns of intact proteins. At this point conventional bottom-up methods 
provide greater sensitivity and better detection limits than top-down approaches, although 
in the context of identifying crosslinks the bottom-up LCMS/MS methods continue to be 
confounded by the difficulty of pinpointing low abundance crosslinked peptides in a 
complicated milieu of unmodified peptides. As algorithms for interpreting the 
fragmentation patterns of intact crosslinked proteins improve, the potential to examine 
species containing multiple simultaneous crosslinks will support construction of more 
comprehensive maps of integrated interactions and more detailed conformational insight. 
In addition, the possibility of examining interactions of proteins containing post-
translational modifications, although challenging, represents a compelling opportunity 
arguably best addressed by top-down methods that can track combinatorial patterns of 
modifications.    
To expand this top-down UVPD methodology to crosslinking applications 
involving larger protein systems, significant improvements in chromatographic resolution 
are needed to separate isomers, possibly by employing a two dimensional strategy such as 
ion exchange chromatography followed by reversed-phase LC. Additionally, HCD of 
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larger proteins typically yields low sequence information. More focus must be placed on 
implementing UVPD to accomplish larger crosslinked samples. This approach offers 
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Chapter 4:  Structural Characterization of Dihydrofolate Reductase 




The step-wise reduction of dihydrofolate to tetrahydrofolate entails significant 
conformational changes of dihydrofolate reductase (DHFR). Binary and ternary 
complexes of DHFR containing co-factor NADPH, inhibitor methotrexate (MTX), or 
both NADPH and MTX were characterized by 193 nm ultraviolet photodissociation 
(UVPD) mass spectrometry.  UVPD yielded over 80% sequence coverage of DHFR and 
resulted in production of fragment ions that revealed the interactions between DHFR and 
each ligand. UVPD of the binary DHFR●NADPH and DHFR●MTX complexes led to an 
unprecedented number of fragment ions containing either an N-terminal or C-terminal 
protein fragment still bound to the ligand via retention of non-covalent interactions. In 
addition, holo-fragments retaining both ligands were observed upon UVPD of the ternary 
DHFR●NADPH●MTX complex. The combination of extensive holo and apo fragment 
ions allowed the locations of the NADPH and MTX ligands to be mapped, with NADPH 
associated with the adenosine binding domain of DHFR and MTX interacting with the B 
loop. These findings are consistent results with previous crystallographic evidence. 
Comparison of the backbone cleavage propensities for apo DHFR and its holo 
counterparts revealed significant variations in UVPD fragmentation in the regions 
expected to experience conformational changes upon binding NADPH, MTX, or both 
ligands.  In particular, the subdomain rotation and loop movements which are believed to 
occur upon formation of the transition state of the ternary complex are reflected in the 
UVPD mass spectra.  The UVPD spectra indicate enhanced backbone cleavages in 
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regions that become more flexible or as suppressed backbone cleavages for those regions 
either shielded by the ligand or involved in new intramolecular interactions. This study 
corroborates the versatility of 193 nm UVPD mass spectrometry as a sensitive technique 
to track enzymatic cycles that involve conformational rearrangements.  
4.2 INTRODUCTION 
The use of mass spectrometry in the field of structural biology has accelerated in 
recent years due to the advent of more effective means of transporting native-like 
proteins into the gas phase, as well as refinement of methods used to probe protein 
structures such as hydrogen-deuterium exchange and tandem mass spectrometry.1,2  Many 
of the original studies that explored the use of mass spectrometry for structural biology 
applications  utilized covalent labeling or crosslinking of proteins and protein-ligand 
complexes in solution,  followed by proteolytic digestion, separation, identification, and 
sometimes quantification of probe-modified or crosslinked peptides to reveal information 
about the solvent accessibility and interacting regions of the proteins.1 More elegant 
strategies based on hydrogen-deuterium exchange of the protein backbone amide 
hydrogens have gained popularity due to their single residue resolution and sensitivity to 
conformational changes.2  Most of these methods have utilized a bottom-up workflow in 
which the proteins of interest are enzymatically digested prior to analysis of the 
constituent peptides, thus providing an indirect means to correlate protein structure with 
peptide-level outcomes. Since the development of new, widely-accessible high 
performance mass spectrometers, there has been growing interest in employing top-down 
approaches for structural biology investigations, thus allowing evaluation of intact 
proteins transported to the gas phase.3–25 Collisional, electron-based and photon-based 
activation methods have been used to analyze the intact proteins.22,26–32 These methods 
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have proven effective for quantifying covalent labeling or hydrogen-deuterium exchange 
of proteins to the same degree, if not more completely, than the corresponding bottom-up 
approaches on proteins below 30 kDa.3–6,8,14   
Compelling new advances in the application of mass spectrometry to structural 
biology problems have been inspired by the recent successes in transporting presumed 
native-like proteins and protein complexes to the gas phase from buffered solutions via 
native spray methods.11,33  This has opened up the possibility of using mass spectrometry 
to directly interrogate native-like protein structures, primarily using MS/MS methods to 
disassemble the complexes, sequence the proteins, and draw conclusions about protein 
conformation based on fragmentation behavior.10,11,15,21,22,34–39  One hallmark of native 
spray is the adoption of much lower charge states of the native-like proteins than those 
observed for denatured proteins sprayed from acidic, methanol-containing solutions.  
Although still a subject of debate, it is believed that proteins retain native-like 
conformations to a large extent, thus allowing examination binding interactions of protein 
complexes via an array of MS/MS methods.11,20,21,40  Ion mobility mass spectrometry 
(IMMS) also plays a pivotal role in discerning and studying the three dimensional shapes 
of proteins and protein complexes in the gas phase.16,41 Collision-based activation of the 
resulting protein-ligand or protein-protein complexes leads to ejection of the ligands or 
intact protein monomers or multimers (from multimeric protein complexes), as well as 
some sequence ions from the proteins.12,15,30  Activation of native-like proteins without 
any bound ligands leads to formation of sequence ions that have been correlated with the 
B-factors of the proteins and thus the local stabilities of specific regions.15,34,42 Ultraviolet 
photodissociation (UVPD) in particular provides unsurpassed levels of sequence 
coverage for intact proteins (denatured ones)26,27,43 and has more recently exhibited 
similar levels of performance for native-like proteins and protein complexes.15,34 For the 
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latter, UVPD resulted in conventional sequence ions for which the abundances of ions 
produced upon cleavage of inter-residue bonds mirrored the B-factors of the protein.  In 
addition UVPD generated product ions comprised of a portion of the protein (a,b,c, x,y, 
or z ion) still bound through non-covalent interactions to the ligand.15,44  One recent study 
showed that the abundance of the fragment ions from myoglobin varied as a function of 
heme binding (apo and holo states) in a way that aligned with expected conformational 
changes upon ligand binding.34  Additionally it was recently reported that conformers of 
ubiquitin separated in the gas phase by ion mobility were differentiated based on their 
UVPD fragmentation patterns.39 Electron capture dissociation, electron transfer 
dissociation, and surface induced dissociation have also been used to disassemble native 
proteins or protein complexes in the gas phase.20,22,36,45–48 Collectively, these studies have 
provided growing evidence that native spray, in conjunction with tandem mass 
spectrometry, can be employed to address increasingly advanced questions about the 
nature of protein-ligand interactions in the context of structural biology.13,49  Herein we 
report the use of UVPD to examine binary and ternary protein ligand complexes, as 
described for dihydrofolate reductase (DHFR). 
DHFR is a small protein (~19 kDa, 186 amino acids) that reduces dihydrofolate 
(DHF) to tetrahydrofolate (THF).  THF is the precursor for all folate coenzymes involved 
in numerous biosynthetic pathways.50,51 Nicotinamide adenine dinucleotide phosphate 
(NADPH) serves as a co-factor of DHFR during its catalytic cycle and is oxidized in the 
process.52 The step-wise DHFR reaction has been explored by many methods to elucidate 
the energetics and structural intermediates.51,53–57 An outstanding depiction of the dynamic 
landscape of DHFR catalysis and structural models of key intermediates in the catalytic 
cycle are provided in ref. 56. There are two well defined binding regions in DHFR, the 
adenosine-binding domain and the loop-binding domain.51 Upon both substrate and co-
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factor binding, it has been established that there are specific loop movements, particularly 
in the M20, F-G and G-H loops, responsible for catalyzing the reduction of DHF and 
releasing THF and the oxidized NADP+.51,53,57–59 These loop movements have been shown 
to be key conformational changes through the catalytic cycle. Additionally, DHFR plays 
a pivotal role in the folate cycle that produces thymine.60 Thymine is required for the 
proliferation of rapidly dividing cells, such as those during cancerous metastasis. This 
feature makes DHFR a compelling drug target for the development of clinical 
therapeutics, such as methotrexate (MTX).51,53,61,62 This potent inhibitor of DHFR has also 
been used in combination with NADPH to aide in the creation of models of the transition 
state of the DHFR reaction.51  The fact that DHFR binds both NADPH and MTX makes it 
an attractive candidate for expanding the scope of UVPD for investigation of protein-
ligand complexes. We report here that UVPD can be used to probe DHFR as well as its 
binary and ternary complexes (DHFR•NADPH, DHFR•MTX, and 
DHFR•NADPH•MTX) and to explore the stepwise impact of loop movements and the 
ligand binding sites as revealed by the UVPD fragmentation trends.   
4.3 EXPERIMENTAL 
4.3.1 DHFR Production 
For expression of DHFR, the E. coli folA gene encoding dihydrofolate reductase 
including a C-terminal His6-tag (amplified from DH10B genomic DNA) was cloned into 
the NdeI/PacI sites of pETDuet-1 (Novagen). BL21(DE3) cells containing pETDuet-
DHFR were cultured in 2 L of LB medium and induced with IPTG during mid log phase. 
Cells were harvested by centrifugation at 8000 x g for 10 min and resuspended in 20 mL 
of wash buffer (100 mM Tris, 150 mM NaCl, 1 mM EDTA at pH 8.0) with protease 
inhibitor cocktail (cOmplete, mini EDTA free, Roche) and lysozyme at 1 mg.mL-1. 
 58 
Following a 20 min incubation at 4 °C cells were lysed by sonication (Model 500, Fisher 
Scientific) and clarified three times by centrifugation at 35000 x g for 30 min. Lysate was 
filtered through a 0.2 μm membrane and DHFR was recovered by IMAC using Ni-NTA 
resin and gravity flow columns. Eluate was concentrated and dialyzed against 50 mM 
NH4OAc pH 6.5, followed by purification to apparent homogeneity by size exclusion fast 
protein liquid chromatography (FPLC).  
4.3.2 Mass Spectrometry 
DHFR solutions were prepared by incubation of 15 µM DHFR stock in 50 mM 
ammonium acetate at pH 6.5 with 20x excess NADPH, methotrexate (MTX), or  
NADPH+MTX, respectively, for 30 minutes at room temperature.   All ligands and 
reagents were obtained from Sigma Aldrich.  Each sample was cleaned six times with a 
10 kDa molecular weight cut-off filter (Millipore, Darmstadt, Germany) and diluted to 7 
µM with 50 mM ammonium acetate pH 6.5 for the native protein samples, while the 
denatured protein sample was filtered into 50:49:1 (water:acetonitrile:formic acid). 
Samples were infused using a 40 nm Au-coated static tip electrospray set-up with an 
applied voltage of 1.2-1.5 kV.  A heated capillary was set at 200°C to assist desolvation 
of the proteins. All experiments were undertaken on a Thermo Scientific Instruments 
Orbitrap Elite mass spectrometer (Bremen, Germany) equipped with a Coherent Excistar 
excimer laser (Santa Cruz, CA) for photodissociation.27   UVPD was performed in the 
HCD cell operated at 10 mTorr helium pressure and using a single 3.0 mJ laser pulse 
(193 nm wavelength) per spectrum.  The 9+ charge state species was selected in every 
case using an isolation width of 15 m/z and an AGC target of 1e5 with a maximum 
injection time of 1 s. 250 scans total were averaged for each spectrum.  
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4.3.3 Data Analysis 
UVPD mass spectra were deconvoluted using the Thermo Xtract algorithm with a 
S/N ratio of 3, then searched through Prosight PC 3.0 modified with custom code to 
include nine UVPD-type ions (a, a•, b, c, x, x•, y, y-1, z). These ion types are consistently 
found by UVPD.27 The searches for and assignments of ligand-containing fragment ions 
(holo fragments in which a segment of the protein retains the ligand via non-covalent 
interactions)  were done in a manner to account for mass shifts corresponding to retention 
of the MTX, NADPH, or MTX+NADPH ligands by the standard sequence ion types 
(a,b,c,x,y,z).  The ligand mass shifts plus up to three extra hydrogens (due to the 
prominence of hydrogen atom (not proton) migrations during activation of proteins by 
UVPD) were treated as variable modifications and were applied as follows:  mass shift of 
454.1713-457.1948 Da for MTX, 743.0750-746.09845 Da for NADPH, and 1198.2541–
1201.2776 Da for MTX+NADPH. All identified ions were normalized relative to the 
total ion current of the respective spectra to allow evaluation of trends for all spectra. 
Fragment ions arising from cleavage of the backbone positions between pairs of adjacent 
amino acids in the protein sequence were collectively summed. For example, all product 
ions arising from backbone cleavages that occur N-terminal to a specific amino acid 
(yielding an, bn, and cn ions) were summed with all the complementary C-terminal product 
ions arising from the next flanking and specific amino acid containing backbone cleavage 
site (yielding complementary xR-(n+1) , yR-(n+1) , and zR-n(n+1) ions) where R is the total number 
of amino acids in the protein. For visualization of the results, residues that displayed a 
significant change in fragmentation yields were highlighted on crystal structures 
representing DHFR•NADPH, DHFR•MTX and DHFR•NADPH•MTX complexes. The 
PDB codes for these structures are 1RX1, 1RG7 and 1RX3, respectively. B-factors were 
extracted from the respective PDB files, as well as for the apo-DHFR form from 5DFR. 
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All visualizations were performed using Pymol 1.3 software. Pymol was also used to 
search for polar contacts with a 4.0 Å cutoff.  All UVPD experiments were repeated at 
least three times. A structural representation of DHFR based on X-ray crystal structure 
1RX3 is shown in Figure 1 with the helices and binding domains labelled and color-
coded. 
 
Figure 1. Schematic figure of DHFR highlighting the subdomains as well as the well-
defined loop regions.  Selected residues are numbered. NADPH is seen in 
blue sticks and MTX is shown in green sticks. This structure was sourced 
from 1RX3.    
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4.4 RESULTS AND DISCUSSION 
In this study, UVPD was used as a tool to characterize previously known ligand 
binding sites and evaluate changes in the structure of DHFR based are reflected by 
variations in the fragmentation patterns of the protein.  DHFR was successfully 
transferred to the gas phase via native ESI conditions to generate apo and holo non-
covalent complexes containing methotrexate (MTX), NADPH, or both NADPH and 
MTX in low charge states (8+, 9+) characteristic of native-like proteins  (Figure 2).  
 
Figure 2. ESI mass spectra of a) denatured DHFR, b) native apo-DHFR, c) native DHFR 
+ MTX, d) native DHFR + NADPH, and e) native DHFR + NADPH + 
MTX solutions. The DHFR stock solution contained NADPH from 
purification which explains the presence of DHFR●NADPH complexes in 
the DHFR spectrum.  
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The 9+ charge state was the most abundant for each DHFR complex, and thus this charge 
state was isolated and subjected to UVPD for all MS/MS experiments.  Examples of the 
resulting UVPD mass spectra are displayed in Figure 3.  
 
 
Figure 3. UVPD mass spectra of the 9+ species of a) native apo-DHFR, b) native 
(DHFR●MTX), c) native  (DHFR●NADPH), and d) native 
(DHFR●NADPH●MTX). UVPD was performed using a single 193 nm 3 
mJ pulse.  
Deconvolution shows that the UVPD spectra are very rich and high quality, containing a 
variety of multi-charged a, b, c, x, y, and z ions, some retaining the NADPH and/or MTX 
ligands (Figures 3 and 4).  In general a/x-type ions were about twice as abundant as b/y 
and c/z ions. UVPD of each of the native apo and holo proteins (9+) yielded at least 81% 
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sequence coverage.  For the native-like DHFR complexes, the pattern of backbone 
cleavages of DHFR (based on formation of N-terminal a, b, and c ions and C-terminal 
x,y, and z ions by UVPD) is influenced by the presence or absence of bound ligands, as 
well as conformational changes that alter the flexibility/stability of specific regions and 
thus the susceptibility to fragmentation.  The fact that absorption cross-sections of 
proteins may vary with charge density or conformation has been postulated previously63 
and echoed in one of our previous studies.34 Variations in molar absorptivities of 
structural elements of proteins in solution (alpha-helices versus coiled/loop regions) have 
similarly been documented.64 
 
Figure 4. Deconvoluted UVPD mass spectra of the 9+ species of a) native apo-DHFR, b) 
native  (DHFR●MTX), c) native  (DHFR●NADPH), and d) native 
(DHFR●NADPH●MTX). UVPD was performed using a single 193 nm 3 
mJ pulse.  
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The complexity of the UVPD mass spectra required careful analysis to 
differentiate and assign ligand-free (apo) and ligand-containing (holo) sequence ions, as 
described in the experimental section.  For the ternary DHFR●NADPH●MTX complex, 
fragment ions containing either NAPDH or MTX or both NADPH and MTX were 
identified.  The average numbers of ligand-containing fragment ions found for each 
DHFR complex are summarized in Figure 5.  
 
Figure 5. The average number of holo fragment ions identified containing a) MTX, b) 
NADPH, or c) MTX●NADPH produced upon UVPD of the binary 
complexes (DHFR●MTX) (in blue in a) or (DHFR●NADPH) (in blue  in b) 
or the ternary (DHFR●NADPH●MTX) complex (red in a,b, and c).  
The DHFR●MTX complex produced 46 unique methotrexate-containing 
fragment ions, and 135 unique NADPH-containing fragment ions were obtained from the 
DHFR●NADPH complex. For the multi-ligand ternary  DHFR●NADPH●MTX 
complex, a total of 212 unique holo fragments were identified upon UVPD, including 
106 retaining NADPH, 36 retaining methotrexate, and 70 containing both NADPH and 
methotrexate.  In summary, NADPH was retained in a greater number of sequence ions 
than was MTX, and MTX was retained in more sequence ions for the ternary 
DHFR●NADPH●MTX complex than for the binary DHFR●MTX complex. In addition, 
NADPH was retained more frequently than MTX upon dissociation of the ternary 
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DHFR●NADPH●MTX complex.  In fact MTX was retained more often in conjunction 
with retention of NADPH than retention of MTX alone. This latter result suggested that 
the ternary DHFR●NADPH●MTX complex engaged in different and/or stronger 
interactions with the MTX ligand than found in the binary DHFR•MTX complex.  The 
detection of sequence ions retaining both NADPH and MTX for the ternary 
DHFR●NADPH●MTX complex was particularly interesting, thus signaling the survival 
of the non-covalent interactions between the protein and two different ligands during the 
photoactivation and dissociation process. 
 
Figure 6. TIC abundance % per residue plots of summed holo + apo product ions from 
DHFR and its respective complexes DHFR●NADPH, DHFR●MTX, and 
DHFR●NADPH●MTX. The color code used for each protein is shown in 
the legend.  Standard deviations were calculated from four replicates.   
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Each UVPD mass spectrum was processed to calculate the relative fragmentation 
propensities between each pair of amino acids in the sequence (i.e. based on backbone 
cleavages between every pair of residues; summing those C-terminal x,y,z and N-terminal 
a,b,c ions arising from each backbone site as described in the experimental section). The 
backbone cleavage propensities are summarized in graphical form in Figure 6, with the 
results for apo-DHFR overlaid with the corresponding results for each of the three 
complexes (DHFR●NADPH in 6A, DHFR●MTX in 6B, and DHFR●NADPH●MTX in 
6C). A number of notable differences were observed upon inspection of the 
fragmentation trends for apo-DHFR relative to its complexes:  cleavage at some 
backbone sites was enhanced; others were significantly suppressed upon ligand binding.  
To aid in visualization of the regions of the protein for which fragmentation was 
enhanced or suppressed, the residues corresponding to those backbone cleavage sites are 
highlighted on the structures of the various DHFR complexes in Figure 7.  The structural 
elements and sub-domains of DHFR are illustrated in Figure 1.  Selected amino acids are 
numbered to facilitate visual orientation of the protein relative to the backbone sites for 
which cleavage is altered going from the apo-protein to the holo-protein complexes.   In 
Figure 7, the change in fragmentation propensity for each DHFR complex is scaled 
relative to the fragmentation propensity of apo-DHFR. A decrease in backbone 
fragmentation (suppression of fragmentation) is highlighted in binned cool colors (cyan, 
blue, purple) on each crystal structure, and increases in backbone fragmentation 
(enhancement of fragmentation upon ligand binding) are binned into warm colors 
(yellow, orange, red).  For native-like proteins or protein-ligand complexes in the gas 
phase, the suppression or enhancement of specific backbone cleavage sites upon UVPD 
is modulated by two primary effects:  “shielding” of backbone sites by non-covalent 
interactions with the ligands or involvement in other intramolecular interactions (thus 
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suppressing fragmentation of those regions) or enhancement of backbone fragmentation 
due to increased conformational flexibility (higher B value).15,34 Regions with greater 
conformational flexibility should have fewer intramolecular interactions than the more 
rigid regions. Therefore, fewer intramolecular interactions must be disrupted in order to 
release pairs of fragment ions (N-terminal and C-terminal products) when a particular 
backbone bond is cleaved, thus accounting for higher UVPD yields.  Moreover, as 
mentioned above absorption cross-sections of different structural elements of proteins are 
known to vary in solution,64  thus potentially translating to variations in local 
absorptivities in the gas phase. 
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Figure 7. Those residues which had an enhanced (positive) or suppressed (negative) 
change in UVPD fragmentation upon comparison of apo-DHFR and a) 
DHFR●NADPH, b) DHFR●MTX, and c) DHFR●MTX●NADPH as well as 
comparison of d) DHFR●NADPH to DHFR●MTX●NADPH were 
highlighted according to the colored bins. In each case, the increase 
(enhancement) or decrease (suppression) in UVPD fragmentation yield is 
shown as a percentage representing the change in TIC abundance.  Crystal 
structures 1RG7, 1RX1, and 1RX3 were used to represent the DHFR● 
MTX, DHFR●NADPH, and DHFR●MTX●NADPH complexes, 
respectively.  
Upon comparison of the backbone fragmentation trends for apo-DHFR and 
DHFR●NADPH, the most notable enhancement in fragmentation occurs in the region of 
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the M20 loop (particularly backbone cleavages associated with residues 12-25), as well 
as from residues 37 to 41 (Figure 6a and Figure 7a). For the same comparison, 
significant suppression of UVPD fragmentation occurred in the adenosine binding 
domain (ABD) in the loop regions from residues 51 to 54, 62 to 65, and 84 to 88. There 
were only a few backbone cleavages in the ABD that were enhanced for the 
DHFR●NADPH complex relative to DHFR (cleavages adjacent to residues 55, 56, 95, 
and 96). Some suppression of UVPD occurred in the helices of the ABD (namely in the 
C, E, and F helices), most notably adjacent to residues 102-104 in the F-helix.   This 
suggests that NADPH binding causes a conformational shift of the M20 loop as well as in 
the ABD, specifically in the loop region containing residues 62 to 65. These changes in 
the UVPD pattern parallel some of the insights drawn by Sawaya et al. whom reported 
the most in-depth crystallographic analysis of the loop and subdomain movements of 
DHFR and its NADPH complexes.51 They mapped the binding of the adenosine portion 
of NADPH to the ABD as well as the shift the M20 loop from a disordered or open 
conformation to a closed conformation upon NADPH binding.51 Sawaya et al. also 
reported that the transition from an open to closed state resulted in disruption of hydrogen 
bonds between residues N23 and S148.51 While a large change in the UVPD cleavage 
pattern is not observed next to residue S148, there is a substantial enhancement in 
backbone cleavage adjacent to residues L24 and P25 which directly neighbor N23.  Also 
notable is the lack of significant changes in cleavage of the backbone sites in the F-G 
loop which are presumed to maintain hydrogen bonds with the M20 loop in the 
DHFR●NADPH complex.51 
Sawaya et al. determined that apo-DHFR and its DHFR●MTX complex had 
similar crystal structures overall; however, the M20 loop was disordered in the apo-
DHFR structure but upon binding MTX the M20 loop adopted a more stable open 
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conformation.51 The main interaction between DHFR and MTX was purported to involve 
the (p-aminobenzoyl)glutamate (pABG) section  of MTX and helix B of DHFR (see 
structural guide in Figure 1) which arose from significant hydrophobic interactions.51  
Such interactions are anticipated to be diminished in the gas phase, thus rationalizing 
both the lower retention of MTX in the fragment ions produced upon UVPD of the binary 
DHFR●MTX and ternary DHFR●MTX●NADPH complexes as well as the relatively 
modest amount of change in fragmentation between the apo-DHFR and DHFR●MTX 
complexes (Figure 6b). However, there are still some notable enhancements in UVPD 
fragmentation for the DHFR●MTX complex relative to apo-DHFR.  These changes are 
most prominent in the M20 loop, specifically enhancements in backbone cleavage 
adjacent to residues 17-18 and in helix B (next to residues 34,37,38,40, and 41). These 
changes in UVPD within the M20 loop are rationalized based on an ordering of the loop 
upon MTX binding and the interaction of helix B with MTX. In comparison to the 
DHFR•NADPH complex, there is little suppression of backbone cleavage of DHFR in 
the DHFR●MTX complex and virtually no changes in UVPD in the ABD region (which 
is remote from the MTX binding site based on the crystal structure).  
Upon inspection of the UVPD fragmentation trends for the ternary 
DHFR●MTX●NADPH complex (Figure 6c and Figures 7c and d), there is a significant 
increase in the number of backbone cleavage sites suppressed or enhanced for the ternary 
complex in comparison to apo-DHFR or the binary complexes. Most of the changes 
mirror those already noted upon the binding of NADPH, such as suppression of 
fragmentation in the ABD and enhancement of fragmentation in the M20 loop.  However, 
there are new enhancements when both ligands are affiliated with DHFR. These new 
regions of enhancement occur in the F-G and G-H loops and in the central beta sheet of 
the enzyme.  
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It has been suggested previously that the ternary DHFR●MTX●NADPH complex 
mimics and exhibits properties similar to that of the active protein transition state for the 
reduction of dihydrofolate (DHF) to tetrahydrofolate (THF).51 Upon reduction of DHF, 
the M20 loop adopts an occluded state which results in disruption of hydrogen bonds 
between residues G121 and D122 from the F-G loop and residues G15 and M16 from the 
M20 loop.51 Additionally upon this M20 loop transition, residue S148 from the G-H loop 
reforms a hydrogen bond to N23.51 Other conformational changes occur during this 
transition-like state, including binding of NADPH and a twisting of the beta-sheet 
between strands A and E. These conformational changes are mirrored by large 
enhancement of backbone fragmentation upon UVPD, spanning both the F-G loop (next 
to residues 115,116, 119-123, 125, 127-130) and G-H loop (next to residues 141-150), 
and with a lower degree of enhancement of fragmentation in the M20 loop (residues 14-
16, 18-20, and 22). This low enhancement of UVPD in the M20 loop suggests that the 
M20 loop may be much less dynamic and instead maintains a more closed and rigid 
conformation. A small amount of suppression of fragmentation is also observed adjacent 
to residues 24 and 25 in the M20 loop. Interestingly, as noted above for the binary 
DHFR●NADPH complex the cleavage adjacent to these residues (24 and 25) was 
enhanced, presumably because the hydrogen bond between S148 and N23 was disrupted 
upon NADPH binding.  All of these changes from UVPD tracked well with the transition 
state mechanism of DHFR discussed above. While that transition state explanation 
evolved from a crystallographic analysis of solid state (static) structures,50 the UVPD 
trends offer a dynamic depiction dependent on disruption and formation of hydrogen 
bonds or other electrostatic interactions that influence the propensity for backbone 
cleavages upon UVPD. There are also compelling changes in UVPD fragmentation 
occurring in the region of DHFR that directly contacts the MTX ligand. Certain backbone 
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cleavages increased in helix B (adjacent to residues 29, 32, and 34), whereas there was a 
significant suppression of backbone cleavages in the ABD region nearest the MTX 
binding site  (next to residues 52,53 and 55-59). This is suggestive of a stronger binding 
interaction occurring in the ternary DHFR●MTX●NADPH complex in comparison to the 
DHFR●MTX binary complex discussed above.  
The pattern and relative abundance of ligand-containing (holo) sequence ions 
produced upon UVPD are displayed as a function of the backbone cleavage site in Figure 
8 and are classified as N-terminal or C-terminal ions. These types of maps are useful for 
discerning the location of the ligands upon dissociation of the non-covalent protein-
ligand complexes.  
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Figure 8. Plots of the N-terminal (blue) and C-terminal (red) holo fragment ions shown 
relative to the backbone cleavage site and produced upon UVPD of 
DHFR•NADPH, DHFR•MTX and DHFR•NADPH•MTX complexes, 
including those fragment ions retaining MTX arising from (a) DHFR•MTX 
and (b) DHFR•NADPH•MTX, those fragment ions retaining NADPH 
arising from (c) DHFR•NADPH and (d) DHFR•NADPH•MTX, and those 
fragment ions retaining both MTX and NADPH arising from (e) 
DHFR•NADPH•MTX. 
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The identified holo ions represent a significant portion of the fragment abundance per 
residue and sometimes are responsible for 100% of the ion current affiliated with 
backbone cleavages at a particular residue (Figure 9).  
 
Figure 9. Plots of the relative abundance of N-terminal (blue) and C-terminal (red) holo 
fragment ions versus the total abundance of fragment ions at each residue. 
This data was produced by UVPD of DHFR•NADPH, DHFR•MTX and 
DHFR•NADPH•MTX complexes, including those fragment ions retaining 
MTX arising from (a) DHFR•MTX and (b) DHFR•NADPH•MTX, those 
fragment ions retaining NADPH arising from (c) DHFR•NADPH and (d) 
DHFR•NADPH•MTX, and those fragment ions retaining both MTX and 
NADPH arising from (e) DHFR•NADPH•MTX. 
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As expected, those fragment ions that retain NADPH for the DHFR●NADPH complex 
differ from those that retain MTX for the DHFR●MTX complex, an outcome anticipated 
based on the different binding sites of each ligand. For example, the NADPH ligand is 
known to interact with residues in the M20 loop as well as those found in the ABD based 
on the extensive array of N- and C-terminal holo fragment ions that contain these same 
stretches of amino acids. These amino acids are highlighted in purple in the space-filled 
model of DHFR in Figure 10 and include residues 13, 14, 16-18, 59, 75, 77, 80-84, 98-
101, 104, 112, 153, 159, and 162. This result is generally consistent with the interaction 
of NADPH with the M20 loop (residues 9-25) and the ABD (residues 38-107),50 in 
particular involving polar contacts between DHFR (residues 7, 18, 19, 44-46, 63, 64, 96-
98, and 102) and NADPH.  (Polar contacts were found using PyMol with a 4 angstrom 
cutoff from analysis of crystal structure 1RX1.) The holo fragment ions produced upon 
UVPD do not overlay perfectly with the contact residues 7, 44-46 or 63-64 predicted 
from PyMol.  However, there are both N-terminal and C-terminal holo-ions containing 
NADPH based on backbone cleavages adjacent to the predicted residues at 9 and 10 as 
well as 65-67.  The proximity of these residues with those from the PyMol prediction 
provides compelling evidence that the holo fragment ions produced by UVPD reflect the 
NADPH binding site.  
The MTX ligand was less consistently retained following UVPD and thus fewer 
informative holo sequence ions were produced (Figure 8c).  There are relatively few 
overlapping C-terminal and N-terminal holo ions that are particularly diagnostic for 
elucidation of the ligand binding site. The MTX-containing fragment ions occurred from 
backbone cleavages adjacent to residues 43, 71, 81, 83, 85, and 122. There were also N- 
and C-terminal holo ions from backbone cleavages at residues 18 and 19. In general 
MTX is known to primarily interact with residues in the loop domain (1-37 and 108-159) 
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and specifically with residues 5, 27, 52, 57, 94, and 100 based on polar contacts from 
crystal structure 1RG7.50 The low frequency of holo fragment ions prohibited more 
detailed assessment of the MTX binding site based on the UVPD data.  
 
Figure 10. Space filling model of NADPH (in multicolor spheres) and the predicted  
(purple spheres) interacting residues from UVPD fragmentation. These 
residues show overlapping N and C termini holo ions. Other holo ions from 
the N-terminus are also highlighted in blue and others from the C-terminus  
are highlighted in red (non space filling). 
UVPD of the ternary DHFR●NADPH●MTX complex resulted in an extensive 
array of NADPH-containing fragment ions (Figure 8b and 8e) encompassing many of 
the same ones as observed for the DHFR●NADPH complex, with some exceptions.  For 
the ternary DHFR●NADPH●MTX complex there are a more elaborate array of C-
terminal ions and a stretch of missing C-terminal ions corresponding to cleavages 
adjacent to residues 34 to 38 that were notable for the binary DHFR●NADPH complex.   
The latter residues encompass or border helix B.  Helix B is known to directly interact 
with MTX,50  thus explaining the potential suppression of cleavage of those backbone 
sites upon UVPD of the ternary complex in the present study. Additionally, the 
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production of MTX-containing N-terminal fragments arising from backbone cleavages 
from residues 13 to 23 was observed upon UVPD of the ternary DHFR●NADPH●MTX 
complex (Figure 8d and 8e) in addition to backbone cleavages from 9-12 and 17-19 
previously noted upon UVPD of the binary DHFR•MTX complex.  The enhancement in 
the number and variety of MTX-containing fragment ions for the ternary complex 
suggests some sort of modulation of MTX binding in conjunction with NADPH binding 
which causes the M20 loop (residues 9-25) to change conformation.  
There is less noticeable overlap in the sequence ions that retain solely MTX or 
solely NADPH for the ternary DHFR●NADPH●MTX complexes relative to the 
corresponding holo sequence ions observed upon UVPD of the binary DHFR●NADPH 
and DHFR●MTX complexes (i.e. Figure 8a versus 8b and 8c versus 8d).   For example, 
there are many more C-terminal ions that retain NADPH for DHFR●NADPH (Figure 
8a) than for DHFR●NADPH●MTX (Figure 8b).  In contrast, there are more N-terminal 
ions that retain MTX for DHFR●MTX (Figure 8c) than for DHFR●NADPH●MTX 
(Figure 8d). This may be explained by the fact that NADPH is mainly associated with 
the ABD which is largely composed of the middle of the N-terminal half of the protein, 
and MTX is known to interact with the helix B region of the loop domain,  thus 
“splitting” the holo N-terminal ion current. In terms of the fragment ions that retain both 
ligands upon UVPD of the ternary DHFR●NADPH●MTX complexes,  the N-terminal 
fragments showed significant overlap with the N-terminal NADPH-containing fragment 
ions from DHFR●NADPH (Figure 8a versus 8e).  This results suggests that NADPH 
does not “migrate” significantly upon addition of the second ligand (MTX) nor does the 
UVPD process cause significant ligand rearrangement.  The fragment ions that retained 
both MTX and NADPH upon UVPD of the DHFR●NADPH●MTX complexes are for 
the most part ones that mirror ones that retained NADPH or MTX alone.  This 
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complementarity is consistent with maintenance of the same networks of non-covalent 
interactions that retain NADPH at one region of the protein and MTX at another. 
4.5 CONCLUSION 
This study demonstrates the versatility of 193 nm UVPD for deciphering protein-
ligand interactions in native-like ternary protein complexes. The retention of non-
covalent interactions upon UV photoactivation allows the determination of ligand binding 
sites based on observation of ligand-containing (holo) product ions as well as suppression 
of backbone cleavages compared to the same backbone cleavages in the ligand-free (apo) 
protein. The UVPD trends correlate well with previously determined crystal structure 
information. Interpretation of the two pools of product ions (holo and apo) gives a more 
complete picture of the structural changes that DHFR undergoes upon NADPH and MTX 
binding. In particular, the changes in abundances of the holo and apo fragment ions 
reflect the conformational changes of DHFR that accompany the ligand binding events. 
The large array of holo fragment ions containing an N-terminal or C-terminal portion of 
the protein and either NADPH, MTX or both NADPH and MTX ligands allowed the 
locations of each ligand to be determined in a manner that reflected the subdomain 
rotation and loop movements of DHFR upon interaction with the two ligands.   The 
ability to examine ternary complexes (in addition to binary complexes and individual 
proteins) makes UVPD-MS a compelling new approach for addressing increasingly 
complicated questions in the arena of structural biology with numerous potential 
implications for studies of enzyme inhibitors and the drug discovery process.  The 
potential sensitivity of UVPD to the impact of single point mutations on protein 
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Chapter 5:  Characterization of Trimethoprim Resistant E. coli 
Dihydrofolate Reductase Mutants by Mass Spectrometry and P21L 




As antibiotic resistance continues to grow and is being recognized as a worldwide 
problem efforts are being concerted to understand how mechanisms of resistances are 
acquired or evolved so that more effective inhibitors can be generated to attack these 
resistant pathogens. One potentially pathogenic bacterium, Escherichia coli, which is 
primarily responsible for bladder infections, has shown significant resistance to the 
standard antibiotic for this infection, trimethoprim (TMP) which inhibits dihydrofolate 
reductase (DHFR) thus halting tetrahydrofolate production. The resistance is achieved 
through single point mutations in the protein. Two clinically relevant resistant mutations 
were studied P21L and the W30R mutations. These mutations were characterized, along 
with the WT DHFR, by a variety of methods to understand the kinetics, thermodynamics, 
and structure of protein by using Michaelis-Menten and inhibitory kinetics, size exclusion 
chromatography, and native-mass spectrometry with ultraviolet photodissociation, 
respectively. Briefly, it was found that the W30R mutation had significantly less kinetic 
fitness for THF production, both mutants were more susceptible to dissociation or formed 
less stable complexes, and main structural changes were seen in substrate binding pocket 
for W30R while the P21L mutant saw the most change in the M20 loop as well as the c-
terminal portion containing the essential G-H functional loop. With this compilation of 
these studies it is suggestive that these mutations are conferring resistance through 
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separate mechanisms. Additionally, a novel propargyl-linked antifolate was shown to be 
potent against the P21L mutation. 
5.2 INTRODUCTION 
Growing concerns about antibiotic-resistant strains of E.coli, as well as numerous 
other pathogenic bacteria, have spurred efforts to expand the pipeline of inhibitors and 
better understand their interactions with protein targets.1–3 As one example, dihydrofolate 
reductase (DHFR) is a protein found in all organisms and plays a key role in converting 
dihydrofolate into tetrahydrofolate, a process essential for the synthesis of purines and 
thymidylic acid.4  The structures of DHFR in Gram-negative bacteria are distinctive from 
DHFR in mammalian cells, thus allowing development of inhibitors that are selectively 
active for bacterial DHFR. Owing to its high affinity for bacterial dihydrofolate reductase 
(DHFR), trimethoprim (TMP) has been one of the most widely used antibiotics for the 
treatment of bladder infections.1–3,5  However, multiple strains of E. coli have developed 
resistance to TMP through chromosomal and point mutations which ultimately modulate 
the structure of DHFR and allow retention of function even in the presence of previously 
successful antibiotics.1–3,6,7 This growing global health threat of antibiotic-resistant 
bacteria has motivated the search for new inhibitors for antibiotic-resistant pathogens.8   
Specifically E. coli has developed the ability to become resistant to trimethoprim (TMP), 
one of the most commonly used antibiotics for bladder infections, through several 
chromosomal and point mutations in the protein dihydrofolate reductase (DHFR).1–3,6   
The ability to assess protein interactions with high sensitivity by mass 
spectrometry has proven to be a powerful new approach in recent years. The spectrum of 
mass spectrometry strategies ranges from those that utilize covalent labelling,9 non-
covalent labelling10 and crosslinking methods11 to decipher solvent-accessible regions of 
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proteins in the absence or presence of other proteins, ligands, or inhibitors, to those that 
use native mass spectrometry to evaluate stoichiometries of protein complexes12–14 and to 
correlate fragmentation patterns with conformational variations.15,16 Native mass 
spectrometry entails spraying proteins from solutions containing high concentrations of 
volatile salts to add the preservation of non-covalent interactions and native-like 
conformations of proteins as they are transferred to the gas phase.  Native mass 
spectrometry has been applied to membrane proteins and whole virus capsids revealing 
biologically relevant insights that have opened new frontiers in the application of mass 
spectrometry in the field of structural biology.17–20  Although, the structural resolution 
obtained from mass spectrometry-based methods rarely rivals that obtained from NMR 
and X-ray crystallography methods, the speed and low sample consumption of mass 
spectrometry give it some compelling advantages.9,10,12,21–23 
Coupling native spray mass spectrometry with non-collisional activation 
techniques such as electron capture dissociation, electron transfer dissociation, and 
ultraviolet photodissociation (UVPD) offers a way to extract additional details about the 
structures of proteins.15,16,24–28 These details include insight into ligand binding 
localization,16,27,29,30 conformational changes,16,31–33 and protein-protein interfacial 
regions.26,34  Native-mass spectrometry can be combined with other auxiliary methods to 
gain activity/thermodynamic information beyond just structural insight.  For example, 
recently a method that integrated a size-exclusion separation method with mass 
spectrometry, termed kinetic size exclusion chromatography (SEC), was developed to 
determine dissociation constants of protein-ligand complexes.35,36 This kinetic SEC-MS 
technique required the use of rather harsh conditions to dissociate the protein complexes, 
and only the small molecule were monitored by mass spectrometry.35 Native MS has also 
been combined with SEC or ion exchange chromatography to study complex protein 
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systems such as oligomers of BSA and protein conjugates for bio therapeutics.37,38 We 
build on this prior SEC-MS work to monitor the survival of protein complexes as well as 
gain qualitative thermodynamic information in the form of koff upon ligand dissociation 
through the SEC column.  
Top-down UVPD-MS has been shown to be a promising method for evaluating 
conformational variations in proteins upon ligand binding, and we recently used this 
strategy for deciphering the conformational changes of DHFR and its inhibition by 
methotrexate (MTX).16 Building on this previous study, we now report the use of UVPD 
to explore TMP-resistant DHFR constructs (P21L and W30R) to characterize their 
structural changes and determine how the mutations drive antibiotic-resistance. The 
structural mechanism of resistance to TMP by DHFR mutations in not yet clear, whether 
a steric hindrance disallowing tight binding of TMP or induction of a thermodynamic or 
kinetic shift favoring protein activity over TMP binding. This type of insight information 
would useful in designing new inhibitors for future therapeutic uses. Additionally, we 
employ size exclusion chromatography (SEC) to monitor the dissociation of protein-
ligand complexes with MS detection. This method allows evaluation of the koff values of 
DHFR-inhibitor complexes. Specifically, two TMP-resistant DHFR variants (P21L and 
W30R) clinically isolated from E. coli are the focus of the present study.5,6,39 In addition, 
a new class of DHFR inhibitors, propargyl-linked antifolates (PLAs), have been shown to 
be potent against an array of different species of DHFR-containing bacteria, including 
wild-type E. coli.40–42 A set of novel inhibitors is evaluated against the two TMP E. coli 
mutants with an emphasis on probing specific interactions that contribute to the inhibition 
of DHFR in the present study. Through the integration of mass spectrometry and kinetic 
data, the relationship between structure and function is bridged to give a more complete 
of how these mutations cause TMP-resistance. 
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5.3 EXPERIMENTAL 
5.3.1 E. Coli DHFR Purification 
The E. coli folA gene encoding DHFR including a C-terminal His6-tag (amplified 
from DH10B genomic DNA) was cloned into pACYCDuet-1 (Novagen). P21L and 
W30R mutations were introduced by QuikChange PCR. BL21(DE3) cells transformed 
with pACYC-DHFR were diluted 1/250 in 0.5 L of terrific broth and induced with (0.5 
mM) IPTG during mid log phase. Cells were harvested by centrifugation at 8000 x g for 
10 min and resuspended in 25 mL of wash buffer (50 mM K 2 HPO 4 , 300 mM NaCl 
and 10% glycerol at pH 8.0) with protease inhibitor cocktail (cOmplete, mini EDTA free, 
Roche) and lysozyme at 0.5 mg/mL. Following 20 min incubation at 4 °C, cells were 
lysed by sonication (Model500, Fisher Scientific) and clarified three times by 
centrifugation at 35000 x g for 30 min. Lysate was filtered through a 0.2 μm membrane 
and DHFR was recovered by IMAC (immobilized metal ion affinity chromatogrphy) 
using Ni-NTA resin and gravity flow columns. Eluate was concentrated and dialyzed 
against 50 mM ammonium acetate (pH 6.5) followed by purification to apparent 
homogeneity by size exclusion FPLC. 
5.3.2 Size Exclusion Chromatography-MS (SEC-MS) 
All size exclusion chromatography experiments were performed using a Dionex 
LC system interfaced to a Thermo Scientific Instruments Velos dual  linear ion trap mass 
spectrometer (San Jose, CA).  The LC effluent was introduced using a HESI source with 
an applied voltage of 4 kV. A 2.1 mm x 30 cm Zenix-C column with 80 Å pore size and 3 
µm particle size was used.  An isocratic mobile phase comprised of 150 mM ammonium 
acetate at pH 6.5 was applied at a flow rate of 80 µL/min. Analytical solutions contained 
12 uM protein in 150 mM ammonium acetate at pH 6.5 with 2% DMSO to facilitate the 
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solubilization of inhibitors. For each run 5 µg of protein was injected onto column.  MS1 
spectra over two m/z regions:  1500-4000 for proteins and complexes and a narrow low 
m/z region around the small molecule inhibitor of interest were collected in an alternating 
fashion. Experiments were performed in triplicate. Peak areas of the detected protein 
complexes were tabulated to calculate the proportion of each eluting from the column.  
5.3.3 Native nano-spray Mass Spectrometry 
Solutions (7 µM protein concentration) were loaded into pulled tip silica emitters 
coated with Au/Pd and sprayed using an applied voltage of 1.9-2.1 kV.   All solutions 
were analyzed using a Thermo Scientific Instruments Orbitrap Elite mass spectrometer 
(San Jose, CA) outfitted with a 193 nm excimer laser as described earlier.43 The buffer 
contained 150 mM ammonium acetate at pH 6.5 with 2% DMSO. Inhibitors were added 
to a 2X molar ratio relative to the protein, and NADPH was added to a 5X molar ratio. 
The 7+ charge state was selected for UVPD fragmentation for each protein or protein 
complex. Spectra were collected at 120 k resolution at 400 m/z with an AGC of 1e5.  For 
UVPD, proteins were activated using a single 2.5 mJ pulse from an unfocused excimer 
laser. 200 scans were averaged for each spectrum.  Experiments were collected and 
analyzed in triplicate. Thermo Xtract with a S/N of 2 was used to deconvolute each 
spectrum. An in-house constructed Web-application was used to analyze the resulting 
deconvoluted data against DHFR sequences with a 10 ppm mass error tolerance. Data 
was further analyzed as described in ref. 17.  
5.3.4 Growth Curve Experiments 
MG16550 E. coli cells were grown and diluted to 0.1 absorbance units at OD of 
600 nm. Cells were then incubated at 37°C with 1 µg/ml or 10 µg/ml concentrations of 
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trimethoprim, methotrexate and the six novel PLAs. UV absorbance measurements were 
recorded at 600 nm for 24 hours every 5 minutes in triplicate.  
5.3.5 Enzyme Kinetics 
Enzyme kinetics were determined by Lineweaver−Burke plots generated by 
enzyme activity assays using 12.5−100 μM DHF with 20 μM NADPH for DHF Km and 
Vmax values or 12.5−100 μM NADPH with 50 μM DHF for NADPH Km values. A 
double-reciprocal plot of enzyme kinetics was generated by plotting 1/V0 as a function of 
1/[DHF] or 1/[NADPH]. The Michaelis-Menten equation was used to determine Km and 
Vmax values. 
5.3.6 Enzyme Inhibition 
Enzyme inhibition assays were performed by monitoring the rate of NADPH 
oxidation by DHFR via absorbance at 340 nm at room temperature in assay buffer 
containing 20 mM TES, pH 7.0, 50 mM KCl, 0.5 mM EDTA, 10 mM beta-
mercaptoethanol, and 1 mg/mL BSA using 0.1 mM NADPH and 2 μg/mL enzyme. 
Inhibitor, in DMSO, was added to the enzyme−NADPH mix and allowed to incubate for 
5 min before the addition of 0.1 mM DHF in 50 mM TES, pH 7.0. The inhibitor 
concentration and volume are based on the conditions that result in a 50% reduction in 
enzyme activity.  
5.4 DISCUSSION 
Upon native spray, ternary complexes containing trimethoprim and co-factor 
NADPH are produced for each variant of DHFR (WT, P21L and W30R) (Figure 1). 
Additionally, the MS1 spectra show that the mutation from tryptophan to arginine for 
variant W30R does not significantly change the resulting charge states, and the 6+ 
complexes are favored for all three variant.   
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Figure 1. Native spray mass spectra for solutions containing each of three constructs of 
DHFR with TMP (2X) and NADPH (5X) in 150 mM ammonium acetate 
and 2% DMSO.  
To shed light upon how the P21L and W30R single-point mutations cause TMP 
resistance, size exclusion chromatography coupled to native spray mass spectrometry was 
employed to monitor dissociation of the DHFR complexes as a means to evaluate relative 
koff  values (where koff refers to a kinetic value that describes the rate of dissociation of the 
protein ligand complex).35,36 Solutions containing various ratios and combinations of one 
DHFR variant (WT or P21L or W30R) with NADPH, DHR, MTX, and TMP were 
incubated, injected onto the SEC column, and the products were monitored.  Figure 2 
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displays extracted ion chromatograms (XIC) for the resulting products for one 
representative solution containing DHFR, NADPH, and TMP.  
 
Figure 2. XICs of the protein complexes observed upon size-exclusion chromatography 
nativespray MS of a solution containing WT-DHFR, NADPH, and TMP 
(1:5:2 molar ratio with a protein concentration of 12 µM). Approximately 5 
ug of protein was injected. The inset shows the averaged mass spectrum 
across the entire SEC peak.  
Binary complexes (DHFR + TMP) and (DHFR + NADPH), and ternary 
complexes (DHFR + NADPH + TMP), as well as the ligand-free protein (apo DHFR) are 
observed, all in the low 6+, 7+, and 8+ charge states that are characteristic of nativespray 
conditions. The proportions of each species were determined from the SEC peak areas. 
The results for each of seven different solutions containing one of the three DHFR 
constructs and either no ligands, 2X DHF, 5X NADPH, 2X MTX, 5X NADPH + 2X 
MTX, 2X TMP, or 5X NADPH + 2X TMP are summarized in the histograms in Figure 
3. The differences in NADPH complexation based on analysis of the solutions containing 
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DHFR + NADPH (5X) are striking, with P21L showing weaker binding (i.e. less 
abundant complexes) than WT followed by the W30R mutant. A less dramatic downward 
trend is also seen for formation of ternary complexes of DHFR+NADPH+TMP when 
comparing WT to both P21L and W30R. 
 
Figure 3. Distribution of complexes detected by native spray MS during SEC elution for 
each solution containing WT-DHFR, P21L, or W30R and various added 
ligands (NADPH, DHF, MTX, and TMP).  The concentration of the protein 
in each solution was 12 µM.  
In particular, the DHFR+NADPH+MTX complexes were lower in abundance for the 
W30R species relative to the WT and P21L variants. For solutions containing each of the 
three DHFR constructs and TMP, the abundances of binary (DHFR + TMP) complexes 
were very low, whereas the abundances of the corresponding ternary complexes (DHFR 
+ NADPH + TMP) were ample.  This interesting outcome suggests that the co-factor 
NADPH plays an important role in stabilization of the DHFR+TMP interactions.  
The SEC-MS chromatograms were also used to monitor the profiles of unbound 
ligands, ones released from the protein complexes during their migration through the 
column (as well as those not bound in the initial incubate injected on column). Those 
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chromatographic peaks with long fronting tails are indicative of complexes with lower 
koff values (i.e. slower dissociation of the protein-ligand complexes). SEC analysis of the 
incubates containing each protein construct and TMP with or without NADPH revealed 
that binary (protein + TMP) complexes were not detected for the W30R construct, thus 
indicating that the binary complexes, if formed, do not survive SEC separation.  The 
binary (protein + TMP) complexes are detected for the WT and P21L constructs (Figure 
4a).  Interestingly, TMP is retained by W30R for ternary complexes containing NADPH 
(Figure 4), as also observed for the WT and P21L constructs. 
 
Figure 4. XIC comparisons of SEC-MS elution profiles for the protein and for TMP from 
solutions containing (a) protein + TMP or (b) protein + NADPH + TMP for 
each of the three DHFR constructs.  
Monitoring the elution profiles of TMP shows distinctive front shoulders for the 
incubates containing WT or P21L and TMP, indicative of slow dissociation kinetics for 
the binary protein + TMP complexes.  The fronting is virtually eliminated for solutions 
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containing each protein, NADPH and TMP, indicative of suppression of TMP release for 
all constructs. The same trend of differing koff is witnessed for the substrate DHF as well 
(Figure 5). However, for DHF there is no protein associated peak, e.g. (DHFR + DHF), 
suggesting a faster koff for DHFR+DHF complexes overall in comparison to the 
DHFR+TMP complexes.  
 
Figure 5. XIC comparisons of elution profiles for dihydrofolate (DHF) from solutions 
containing protein + DHF with respect to each DHFR construct (WT, P21L, 
W30R).  
The negative control methotrexate was also  evaluated in the same manner, and the 
results are highly complex (Figure 6) with multiple peaks in the protein eluting region (6 
- 7 minutes) as well as later in the chromatogram. Due to this complexity, few 
conclusions can be extracted about these binary and ternary systems. Overall there is a 
significantly different elution time in the second bimodal chromatographic peak between 
the DHFR+MTX (Figure 6a) and the DHFR+NADPH+MTX (Figure 6b). This may be 
indicative of different dissociation pathways that are accessed between binary and ternary 
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complexes leading to the slower elution times for the ternary complexes seen in the later 
temporal profiles. Unfortunately, the novel propargyl-linked antifolates were too 
hydrophobic to elute from the column using native solvent conditions and thus could not 
be profiled in the same way by SEC-MS.  
 
Figure 6. XIC comparisons of SEC-MS elution profiles for DHFR and MTX from 
solutions containing (a) DHFR+MTX or (b) DHFR + NADPH + MTX for 
each of the three DHFR constructs  
Elution profiles for the binary (DHFR + NADPH) complexes and ternary (DHFR 
+ NADPH + MTX) and (DHFR + NADPH + TMP) complexes are shown in Figure 7 
(a,b,c). Fronting occurs for each of the three protein constructs, and in a manner that is 
nearly identical which prevents detailed koff comparisons.  However, the release of the 
ligand can be monitored as shown in Figure 7. There are significant differences in the 
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release of NADPH in the presence or absence of the two inhibitors (MTX versus TMP) 
(Figure 7a-c) among the three protein constructs (Figure 7d-f).  
 
Figure 7. XIC traces (upper series) showing elution profiles of NADPH upon SEC-MS 
analysis of solutions containing protein+NADPH, protein+NADPH+MTX 
or protein+NADPH+TMP for each of the three DHFR proteins: (a)WT-
DHFR, (b) P21L, and (c) W30R.  XIC traces (lower series) showing elution 
profiles of NADPH upon SEC-MS analysis of solutions containing WT-
DHFR, P21L or W30R with (d) no added inhibitor (N.I.), (e) addition of 
MTX, and (f) addition of TMP.  
 
For WT DHFR, addition of either MTX or TMP significantly decreases the release of 
NADPH from the complexes (lower peak area in front of the bulk NADPH peak). This is 
interpreted to mean the complex formed has been stabilized thus deterring co-factor 
release during separation. The presence of MTX has a more notable impact on the release 
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of NADPH than does the presence of TMP for the P21L construct, and the release of 
NADPH is less substantially influenced by the presence of MTX or TMP for the W30R 
construct. These observations give evidence for how these single point mutations have 
allosteric effects on the co-factor binding and complex stabilization in addition to 
modulation of the binding of substrate and inhibitors.   
The experiments described above show how native mass spectrometry coupled to 
SEC can be used to evaluate some of the factors that influence the relative stabilities of 
complexes and kinetic factors of complexation.  With respect to examination of 
variations in conformation of the resulting complexes, UVPD can be used to decipher 
structural differences in the complexes based on variation in the extent of fragmentation 
along the backbone of each protein (with or without bound ligands). The UVPD 
fragmentation yields reflect the efficiencies of backbone cleavages along the protein.  An 
example of a typical UVPD mass spectrum, the sequence coverage map constructed from 
the UVPD mass spectrum, and the relative extent of backbone cleavage at each position 
is shown for P21L DHFR protein in complex with NADPH in Figure 8. The UVPD mass 
spectra for each protein complex are used to create difference plots which allow facile 
comparison of the changes in backbone cleavage efficiencies between proteins or their 
complexes. An example is shown in Figure 9a for the three apo-proteins, in which the 
variations in UVPD fragmentation yields are shown from the N-terminus to the C-
terminus for each of the P21L and W30R constructs relative to WT DHFR.  The 
difference plots in Figure 9a diverge considerably for the two mutant constructs, and the 
most significant variations are color-coded on the protein structures in Figure 9b,c.  
Increases in the efficiency of backbone cleavages of the P21L or W30R complexes 
relative to WT DHFR upon UVPD are highlighted in red and decreases in the efficiency  
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Figure 8. a) Fragmentation of the 7+ P21L DHFR+NADPH protein complex with the 
resulting b) apo ion identification and c) NADPH holo ion identificaiton 
(+745.0906). The sum of the intensities of both apo and holo ions from this 
complex can be seen in panel (d).  
of backbone cleavage are highlighted in blue. Increases or suppression of backbone 
cleavages are presumed to indicate regions of the protein that become more flexible or 
more stabilized due to conformational changes, variations in intramolecular interactions, 
or other factors.  There are relatively modest changes in UVPD fragmentation for the 
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P21L mutant relative to WT-DHFR; however the few changes that are observed are 
located proximal to the M20 loop or in the loop regions surrounding the substrate binding 
pocket.  
 
Figure 9. (a) Differences in UVPD fragmentation efficiencies for P21L (in purple) and 
W30R (in green) relative to WT-DHFR. Large differences in UVPD (those 
with >0.0001 ∆TIC abundance) are highlighted on the DHFR crystal 
structure (1RX3) for P21L (b) and W30R (c). Those residues highlighted in 
blue sticks show UVPD suppression, and those residues highlighted in red 
sticks show UVPD enhancement.  Hot pink indicates the mutated residue. 
More substantial variations in UVPD fragmentation occur for the W30R mutant, 
particularly shifts in backbone cleavage efficiencies in the regions of the 
substrate/inhibitor binding pocket as well as the M20 loop. Residue 21 of DHFR does not 
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play a major role in the core alpha helix/beta sheet composition of DHFR but rather 
occupies a peripheral position. This suggests that the P21L point mutation is less likely to 
cause a significant conformational re-organization of DHFR and instead the mechanism 
of TMP-resistance may originate from a kinetic or thermodynamic modulation in the 
uptake of TMP.  In contrast, residue 30 is a key amino acid in the core structure of 
DHFR, and the W30R mutation replaces a hydrophobic amino acid with a more compact 
hydrophilic residue.  The W30R mutation is anticipated to modulate TMP binding.  
Following the use of UVPD-MS to examine the variations in UVPD 
fragmentation efficiencies of the ligand-free proteins, each of the binary complexes 
(+NADPH, +DHF, +MTX, +TMP, +1038, +1103) and ternary (NADPH + MTX, 
NADPH + TMP, NADPH + 1038, NADPH + 1103) complexes for each DHFR construct 
were examined by UVPD.  The differences between each binary and ternary combination 
were calculated and summed for three key regions of the protein (M20 loop comprised of 
residues 10-24, substrate binding region consisting of residues 25-55, and C-termini 
region containing residues 126-155 which encompasses the G-H loop essential for 
protein activity) (plotted as heat maps in Figure 10).  UVPD yielded low or no 
fragmentation of the backbone for one other essential loop44 (F-G loop, spanning residues 
115-130 in the middle of the protein) and thus could not be evaluated. Cumulative 
summation of the differences in UVPD of the binary or ternary complexes allows a 
convenient way to showcase the most significant changes in fragmentation for the large 
array of binary and ternary complexes and thus probe the complete conformational space 
of each mutant and ligand combination.  
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Figure 10. Direct comparison of absolute differences in UVPD fragmentation efficiencies 
between each combination of (a) binary and (b) ternary complexes for three 
regions of interest. These regions are the M20 loop (residues 10-24, hot 
pink),  substrate binding region (residues 25-55, orange) and the C-terminus 
(residues 126-155, turquoise). These regions are highlighted on the DHFR 
crystal structure (1RX3) with specific residues  P21 and W30 marked in 
spheres. Each number on the edge of the plot is related to the numbering 
system below it and separated into three different sections where green is 
WT, blue is P21L and red is W30R. Black bar in ternary complex of W30R 
with compound 1038 indicates that no ions in this region were detected.  
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For this phase of the study, two propargyl-linked antifolate inhibitors (1038 and 1103, 
structures shown in Figure 11) were also included to extend the strategy from well-
characterized inhibitors to newly emerging candidates.  
 
Figure 11. Growth curves of E. coli MG1655 cells incubated with 1 µg/ml inhibitor 
(compound 1038,1103, or TMP) relative to the control (no inhibitor added). 
The structures and  IC50 (nM) values for four inhibitors of WT DHFR are 
shown. Multiple curves surrounding the control case represent other tested 
inhibitors that did not impede cell growth. 
The largest consistent changes in UVPD fragmentation occurred over the substrate 
binding pocket region for W30R in both the binary and ternary complexes relative to all 
other ligand and mutant combinations. In particular a significant difference was observed 
for all W30R complexes containing DHF and MTX relative to the WT-DHFR 
complexes.  Additional variations, although not as substantial, were found for the M20 
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loop and C-terminal region of the P21L binary complexes. Interestingly, these two 
regions of the protein interact with each other (particularly the M20 and G-H loops) 
during the enzymatic function of the protein, so it is encouraging that these trends are 
reflected in the UVPD trends through both regions of the protein44.  For the ternary 
complexes, the P21L mutant exhibits the most significant variations in UVPD 
fragmentation in the M20 loop and C-terminal regions.  The UVPD trends for the ternary 
complex (P21L + NADPH + 1103) suggests a different conformational change than 
observed for the corresponding WT and W30R complexes, and the ternary complex 
(P21L + NADPH + MTX) also displays a significant change in UVPD fragmentation 
efficiency in the C-terminal region. It is especially interesting to note that based on the 
UVPD trends, the P21L construct, unlike the W30R construct, does not seem to perturb 
the substrate binding pocket and instead specifically affects the activating loops of the 
protein. 
To support the results derived from the SEC-MS and UVPD-MS methods, 
classical Michaelis-Menten kinetic experiments were performed (Table 1) as well as 
inhibitory kinetic testing (Table 2). The activity of each DHFR variant was evaluated via 
UV-Vis measurements based on monitoring the conversion of NADPH to NADP+ in the 
presence of substrate DHF by UV-Vis at 340nm (Table 1).  
 
Table 1. Michaelis-Menten kinetic parameters for the activity of each protein in the 
presence of substrate DHF. 
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Table 2. Inhibitory kinetic parameters  
Rates of decreasing absorption at 340nm at varying concentrations of DHF and NADPH 
were used to calculate Michaelis-Menten parameters for Km values for DHF and 
NADPH, respectively. Both variants (W30R and P21L) retained activity for conversion 
of DHF to THF. As summarized in Table 1, both the P21L and W30R constructs 
displayed relatively stronger interactions with DHF relative to WT DHFR based on their 
larger Km values. While P21L displayed significantly weaker interactions for NADPH 
based on the Km and W30R showed an order of magnitude stronger interaction NADPH 
than the WT. However, this factor does not seem to perturb the catalytic constant (Kcat) of 
the P21L protein which displays a turnover rate similar to that of the WT protein. The 
W30R construct exhibits an order of magnitude decrease in activity (Kcat) relative to WT 
DHFR in part due to the stronger interaction of the co-factor (NADPH) and its products. 
Upon comparing the efficiency of the enzyme activity (kcat/km) for both substrate and 
co-factor it was seen that the P21L construct is nearly twice as efficient and the W30R 
was a third as efficient in comparison to the WT, with respect to DHF. While measuring 
the efficiency with respect to NADPH the WT is the most efficient while P21L and 
W30R remain comparable with slightly lower efficiency. Overall, this suggests that the 
DHF binding and release for the full enzymatic process is most effected by the TMP 
resistant mutations.  
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While direct comparisons between Km and the qualitative Koff values obtained 
from the SEC-MS measurements cannot be made, they provide complementary kinetic 
and thermodynamic information, respectively. Km is indicative of protein-ligand binding 
(DHF and NADPH), enzymatic activity, and release of products (THF and NADP+) over 
the course of the reaction. Relative koff displays information particularly about the rate of 
release of the unprocessed ligands (DHF and NADPH) or protein complex stability under 
study from a thermodynamic perspective and is related to the first binding steps in the 
enzymatic process. These are two independent parameters to consider when describing 
the enzymatic landscape. For instance, it was seen in general for the SEC-native MS case 
that protein-ligand complexes were most stable in the WT followed by the P21L and 
W30R constructs. Particularly for DHF dissociation, and binary TMP  complexe 
dissociation (DHFR+TMP) the W30R was most unstable. However, inspecting the 
ternary TMP complex (DHFR+TMP+NADPH) the apparent koff was nearly identical for 
the TMP elution(Figure 3b) as well as the NADPH elution (Figure 4f) upon comparison 
of P21L and W30R constructs. While P21L and W30R are more susceptibility for 
dissociation than the WT, these constructs display stronger affinity (lower Km values) 
with respect to DHF which may be reflective of lower energy dissociation pathway for 
substrate binding and subsequent product release. However, in the case of W30R the 
Kcat is diminished by an order of magnitude suggesting a significantly slower product 
release. Specifically by the tighter Km for the mutated W30R with respect to NADPH 
and the release of the NADP+ product. It is also seen that the P21L construct has the least 
affinity (Km) for NADPH, which is consistent with the location of mutation on the M20 
loop which is responsible for NADPH binding.  
Trimethoprim (TMP) is a well-known inhibitor of DHFR with a nanomolar 
binding constant (Table 2). IC50 values calculated for the two DHFR variants, W30R 
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and P21L, exhibited an order of magnitude increase in the inhibitory concentration 
compared to WT DHFR, thus confirming significant resistance to TMP.  The 
complementarity between the relative thermodynamic koff parameters is best revealed by 
comparing the IC50 and Ki values of the positive control inhibitor TMP. Additionally, the 
negative control (MTX) did not cause a large shift in neither the IC50 nor the Ki values 
for either of the two DHFR variants. The expectation for the P21L and W30R variants to 
release TMP more readily than would the WT construct based on its IC50 and Ki value, 
agrees well with the koff SEC data (Figure 3). In addition, the fact that the Ki value is 
greater for W30R and P21L in comparison to the WT indicates that the mutant constructs 
are more susceptible to exchanging the inhibitor for the substrate. In short, the mutant 
constructs exhibit much less specificity overall for TMP than the WT proteins. The 
outcomes from the inhibitory kinetics of TMP align well with the koff information 
determined from the earlier SEC-MS measurements, as well as with the structural insight 
from the UVPD trends. These trends indicated that there was a much broader 
conformational change in the binding pocket of W30R in comparison to the WT and 
P21L proteins. The conformational changes seen in the substrate binding pocket may 
facilitate this greater exchange for the substrate and the doubled IC50 for TMP in 
comparison to the P21L construct. Large conformational changes were not seen in the 
substrate binding pocket for P21L in comparison to the WT. P21L showed significant 
conformational change witnessed in the ternary complexes, specifically 
DHFR+NAPDH+MTX and DHFR+NADPH+1103 in both the M20 loop and c-terminal 
portion of the protein. The above evidence (amongst the other evidence) is suggestive 
that the two mutations induce resistance through two separate mechanisms. 
To further parse out differences in mechanisms of resistance (and inhibition) as 
well as discover inhibitors for these TMP resistant mutants several novel propargyl-
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linked antifolates (PLAs) were investigated. A small panel (6) of novel  candidates was 
tested against wild type E. coli MG1655 cells to determine which ones exhibit positive 
inhibitory activities in vivo (Figure 11). Two of the candidates, 1038 and 1103, caused a 
significant decrease in cell growth at 1 µg/ml. The TMP control quenched nearly all cell 
growth at 1ug/ml, whereas the negative control MTX showed no inhibition of cell 
growth. It has been reported at that MG1655 cells have efflux pumps which render MTX 
ineffective in vivo.45 Upon inspection of Table 2, compound 1103 resulted in large 
increases in the IC50 values for both W30R and P21L mutants relative to the WT protein. 
Compound 1038 was a reasonably effective inhibitor of P21L relative to the WT protein 
with small increase (more potent) in the Ki value and similar IC50s.  The W30R mutant 
remained resistant to the new candidate inhibitors, possibly owing to the removal of a 
large hydrophobic residue (tryptophan) from DHFR in the substrate binding pocket 
which would be expected to interact with the hydrophobic propargyl linker portion of the 
inhibitor. These results further convey the large differences in the modes of action caused 
by the two point mutations of DHFR. 
5.5 CONCLUSION 
Using two separate mass spectrometry centric experiments the structure-function 
relationship of TMP resistant mutants were successfully evaluated revealing two different 
mechanisms of resistance one which directly modulate the core structure of the protein 
(W30R) while the other instills resistance through a more subtle manner adjusting the 
rigidity of the M20 loop (P21L) to aid in TMP release. These mass spectrometry results 
were supported by complimentary Michealis-Menten kinetic and respective inhibitory 
constants (IC50 and Ki) of each evaluated inhibitor. It was found that overall the 
qualitative koff SEC experiments agree the best with the IC50 and Ki values. Perhaps even 
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more exciting is that compound 1038 which has shown to be previously very potent for 
E. Coli DHFR is also as potent for the P21L TMP resistant construct. These results show 
continued promise for propargyl-linked antifolates as effective inhibitors against 
pathogenic DHFR protein species.  
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Chapter 6:  Impact of G12 Mutations on the Structure of K-Ras Probed 
by Ultraviolet Photodissociation Mass Spectrometry 
 
6.1 OVERVIEW 
Native mass spectrometry combined with top-down ultraviolet photodissociation 
(UVPD) was employed to investigate the structural changes occurring from a somatic 
single residue mutation (G12X) of the GTP-ase protein K-Ras. Specifically, the prevalent 
and cancer-related protein K-Ras and its single residue mutants G12X (where X = C, V 
or S) were the focus of this study. G12X mutations of K-Ras are a prevalent oncogenic 
mutation. Complexes between K-Ras or the G12X mutants and guanosine 5’-diphosphate 
(GDP) or GDPnP (a stable GTP analog) were transferred to the gas phase by nano-
electrospray ionization and characterized using UVPD.  Variations in the efficiencies of 
backbone cleavages were observed upon substitution of GDPnP for GDP as well as for 
the G12X mutants relative to WT K-Ras. An increase in the fragmentation efficiency in 
the segment of the protein containing the first 50 residues was observed for the K-
Ras/GDPnP complexes relative to the K-Ras/GDP complexes, whereas a decrease in 
fragmentation efficiency occurred in the section containing the last 100 residues. These 
stretches correspond to the phosphate and guanine binding regions, respectively, and are 
indicative of a change in the binding motif upon replacement of the ligand (GDP versus 
GDPnP). Unique changes in UVPD were observed for each G12X mutant with the 
cysteine and serine mutations exhibiting similar UVPD changes whereas the valine 
mutation was significantly different. The results support that variations in UVPD 
fragmentation reflect changes in conformations or dynamics arising from single amino 
acid mutations that modulate function of K-Ras.   
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6.2 INTRODUCTION 
Proteins containing single amino acid mutations (presumably arising from 
somatic mutations acquired in a given cell over time) are expressed in a large number of 
cancerous tissues.1,2 These mutations can specifically modulate the function of the protein 
in question, a factor which may promote cancer growth.2 For example, single point 
mutations leading to constitutively active members of the rat sarcoma (Ras) family of 
proteins have been implicated in cell cycle progression, proliferation, apoptosis and 
senescence, all important in cancer.3 Within the Ras family of proteins, K-Ras is the most 
frequently mutated isoform, present in 22% of all tumors analyzed and 90% of pancreatic 
tumors.4 Of the point mutations found in K-Ras, 80% are found at codon 12.  At this 
amino acid position, a Gly in wild-type (WT) K-Ras, mutations that introduce larger side 
chains block the ability of GTPase activating protein (GAP) to stimulate K-Ras 
hydrolysis of GTP, thereby locking it into an active state.  Trapping the K-Ras protein in 
an active state leads to abnormally high concentrations of GTP-bound K-Ras, which 
results in upregulation of downstream pathways and unregulated cell proliferation and 
tumor growth.  The particular amino acid substitutions found at the G12 position 
(designated here by G12X) vary in frequency, with G12D being the most prevalent, 
followed by G12V, G12C and others.  These substitutions also vary in frequency by 
cancer type.4  For example, the G12D mutation is often found in colon, lung, pancreatic 
and skin cancer tissues, among others.  The G12V mutation is also widespread but can 
show more prevalence than G12D in skin cancers.  The G12C mutation is extremely 
prevalent in lung cancers, and other G12X mutations, such as G12S appear less 
frequently.4  There is growing evidence that, in addition to differences in distribution by 
cancer type, the identity of the side chain substitution at G12X leads to different 
downstream functional effects (vide infra).  Therefore, development of novel tools for 
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investigating how particular mutations affect the conformation and binding interactions 
of K-Ras in particular, and other disease-relevant proteins in general, would be a 
compelling advance.  
In recent years, mass spectrometry has become an increasingly popular approach 
for addressing a variety of questions in the arena of structural biology.5–7 Strategies using 
chemical probes, including hydrogen/deuterium exchange (HDX) methods, to evaluate 
solvent accessibilities and map protein interfaces and other covalent-labeling methods 
have played a prominent role in advancing the applications of tandem mass spectrometry 
for studying structures of proteins.8–12 These chemical-based methods have been used in 
the context of both bottom-up (proteolytic digestion of probe-modified proteins into 
peptides) and top-down (analysis of intact proteins) modes.  For the probe-based 
methods, typically the solvent accessible regions of the proteins or protein complexes are 
reflected by the abundances of modified peptides (for the bottom-up methods) or the 
abundances of modified fragment ions (for top-down methods).8–12  Perhaps the most 
information-rich approach entails HDX, in which the rate of exchange of the amide 
hydrogens of the protein backbone is correlated with the surface exposure of each 
residue.8,11,12 
While chemical probe methods have been applied with great success to many 
systems, the use of top-down mass spectrometry to examine native-like intact proteins 
and protein complexes has accelerated, especially with advances in MS/MS methods that 
are sensitive to protein structure. Native mass spectrometry involves the use of buffered 
spray solutions containing volatile salts, typically ammonium acetate, which allows 
gentle transfer of proteins into the gas phase in low charge states (compared to proteins 
ionized using conventional nanospray conditions).13–17 Although there are unresolved 
questions about the specific mechanisms of native-spray, it is believed that the charged 
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proteins remain to a large extent folded similarly to the tertiary and quaternary structures 
adopted in solution.18–22 The shapes of proteins ionized by native-spray have been 
evaluated successfully by ion mobility mass spectrometry, in which the measured 
collisional cross sections have been correlated with the sizes of native proteins in 
solution, thus providing evidence that the proteins remain native-like during their transfer 
to the gas phase.23–26 Cross-sections of proteins obtained from ion mobility measurements 
have been shown to increase significantly with charge state, thus signaling their 
unfolding.18 Native MS has gained additional momentum with the growing availability of 
high resolution/high mass accuracy mass spectrometers that have allowed greater 
implementation of MS/MS methods for analysis of intact proteins.27 To date, native mass 
spectrometry has been applied to a large array of applications in structural biology 
including examination of stoichiometries of protein complexes, ligand binding, 
binding/dissociation constants, conformational changes of proteins, and dynamic 
unfolding.13–17,25–33  
With respect to MS/MS characterization of native-like proteins and protein 
complexes, electron-based activation methods, such as electron transfer dissociation 
(ETD)34 and electron capture dissociation (ECD),31,35–38 provide significant diagnostic 
sequence information. The abundances of the resulting fragments have been correlated 
with the degree of flexibility of different regions of the proteins, thus reflecting 
crystallographic B-factors.31,37,39 Interestingly it has also been shown that salt bridges in 
proteins may survive upon electron transfer reactions, resulting in electron transfer but 
without dissociation of the resulting fragments, and the proteins release the 
electrostatically-bound fragment ions upon further activation.34 Another activation 
technique, surface induced dissociation (SID), has proven to be particularly impressive 
for determination of quaternary arrangements of native multi-protein complexes.40,41 A 
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third method takes advantage of high energy excitation via absorption of 193 nm photons 
to give the most extensive backbone fragmentation of proteins by any activation 
method.42,43 Ultraviolet photodissociation (UVPD) has shown unprecedented sequence 
coverage for unfolded proteins as well as their natively-ionized analogs.30,44,32,33 
Additionally, the patterns of backbone cleavages promoted by UVPD not only correlate 
with the average B-factors of residues in proteins (which can reflect thermodynamic 
motions and/or heterogeneity of the crystal lattice among other factors) but also reveal 
ligand binding sites based on suppression or enhancement of fragmentation and retention 
of the ligand by the fragment ions upon protein dissociation.30,33 The UVPD patterns have 
been shown to be modulated for different gas-phase conformers as measured by ion 
mobility mass spectrometry.45,46 Most recently UVPD was used to elucidate ligand 
binding sites and monitor the conformational changes of dihydrofolate reductase (DHFR) 
upon binding of co-factor NADPH and its inhibitor methotrexate.30 At the conclusion of 
this previous study it was proposed that UVPD should be tested on a protein with single 
amino acid mutations to evaluate the sensitivity of UVPD to subtle changes in sequence 
that might (or might not) cause conformational changes of the protein as well as induce 
alterations of ligand binding modes,30 a proposal that catalyzed the present study.   
 In the present study, native spray mass spectrometry and top-down UVPD is used 
to characterize protein-ligand combinations of WT and clinically-relevant G12X mutants 
of K-Ras including G12C, G12S, and G12V.  In our hands, the most common G12D 
variant was not stable upon purification (data not shown).  These K-Ras variants are 
characterized either bound to guanosine diphosphate (GDP) or to guanosine 5’-[β, γ-
imido]triphosphate (GDPnP), a non-hydrolyzable analog of guanosine triphosphate 
(GTP). The structural changes upon GTP hydrolysis of WT K-Ras have been studied 
using conventional biophysical methods and provide a comparative benchmark for the 
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gas-phase UVPD approach used in the present study.47 We compare variations in UVPD 
fragmentation of GDP and GDPnP complexes containing WT K-Ras or the G12C, G12S 
and G12V variants to decipher unique structural changes arising from these single point 
mutations.  
6.3 EXPERIMENTAL 
6.3.1 Protein Expression and Purification 
Recombinant human wild-type K-Ras (isoform 2, residues 1-169 (18,954 Da) was 
heterologously expressed from previously described expression plasmids48 that also 
encode an N-terminal hexahistidine affinity tag followed by a tobacco etch virus (TEV) 
protease cleavage site preceding the rest of the sequence.  Expression and purification for 
the G12C, G12S or G12V variants was the same.  Briefly, the expression vector was 
transformed into Escherichia coli BL21 (DE3) and subsequent cultures were grown in 
Terrific Broth containing kanamycin (50 mg/L) with shaking (250 RPM) at 37 °C until 
the optical density600nm reached 0.4 - 0.6.  Expression was induced through addition of 
isopropyl-β-D-thiogalactoside (IPTG, 0.5 mM)) and incubation was continued overnight 
(approximately 18 h) at 18 °C.  Cells were pelleted by centrifugation at 11,325 × g for 20 
min at 4 °C.  The pellet was harvested and either used immediately for purification, or 
flash frozen in liquid nitrogen and stored at – 80 °C for later use.  A fresh or thawed 
pellet was resuspended in 100  mL Lysis Buffer (20 mM Tris, 500 mM NaCl, 5 mM 
imidazole at pH 8) supplemented with protease inhibitor cocktail (Roche complete EDTA 
free).  β-Mercaptoethanol (2 mM final concentration) was added to the solution and cells 
were lysed by sonication.  Cell debris was pelleted by centrifugation at 39,191 × g for 20 
min at 4 °C and discarded.  The remaining supernatant was incubated for 1 h with Qiagen 
Ni-NTA resin slurry (6 mL) pre-equilibrated in Lysis Buffer.  The slurry was then 
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transferred to a column and washed with Lysis Buffer (50 mL) supplemented with 
imidazole (20 mM).  Hexahistidine-tagged K-Ras was then eluted using Lysis Buffer (10 
mL) supplemented with imidazole (200 mM).  The hexahistidine affinity tag was 
removed by treatment with N-terminal His-tagged TEV protease (1 mg protease for every 
25 mg of total protein) along with supplementation of GDP (1 mg GDP for every 20 mg 
of total protein) and dialyzing overnight against Dialysis Buffer (20 mM Tris, 300 mM 
NaCl, 5 mM imidazole, 1 mM dithiothreitol (DTT) and 0.5 mM EDTA at pH 8).  
Following dialysis, the protein solution was diluted five-fold with Low-Salt Buffer (20 
mM Tris, 50 mM NaCl at pH 8) and supplemented with MgCl2 (5 mM) and GDP (1 mM).  
Uncleaved hexahistidine-tagged K-Ras and N-terminal His-tagged TEV protease were 
removed from the final solution by incubation (1 h) with Ni-NTA resin slurry (3 mL), 
pre-equilibrated with Low-Salt Buffer, followed by centrifugation to pellet and discard 
the Ni-NTA resin.   
Each of the WT, G12C, G12S or G12V K-Ras variants was further purified by ion 
exchange chromatography using a Q-Sepharose Fast Flow column (8 mL, GE Healthcare 
Life Sciences).  The column was washed using wash buffer (20 mM Tris, 100 mM NaCl 
at pH 8).  K-Ras protein was eluted using Elution Buffer (20 mM Tris, 250 mM NaCl at 
pH 8).  Remaining high molecular weight impurities were removed using an Ultracel 50 
kDa molecular weight cutoff (MWCO) filter (Amicon Ultra 4 Centrifugal Filter). The 
filter flow-through containing K-Ras was exchanged into Storage Buffer (10 mM Tris, 25 
mM NaCl at pH 8) using an Ultracel 10 kDa MWCO filter (Amicon Ultra 4 Centrifugal 
Filter) and concentrated to a final concentration of 1 - 2 mg/mL.  Typical yields for each 
of the purified K-Ras variants were 5 - 10 mg / 1 L culture.  
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6.3.2 K-Ras Nucleotide Exchange 
K-Ras variants (30 μM) were incubated in Exchange Buffer (25 mM Tris, , 10 
mM EDTA, 1.5 mM guanosine 5’-[β, γ-imido]triphosphate (GDPnP, Sigma Aldrich), 1 
mM dithiothreitol (DTT) at pH 8) for 1 h.  MgCl2 was subsequently added to the 
incubation to a final concentration of 25 mM, and the mixture was incubated for an 
additional 30 min.  The protein was then exchanged again into Exchange Buffer using an 
Ultracel 10 kDa MWCO centrifugal filter (Amicon Ultra) and the above procedure was 
repeated a second time.  In a final step, the protein was exchanged into a similar buffer 
that lacked EDTA (25 mM Tris at pH 8). This procedure loads K-Ras with the 
nonhydrolyzable GTP mimic, GDPnP and results in approximately 95% GDPnP loading 
as determined by MS (see below).     
6.3.3 Mass Spectrometry 
Equimolar protein/ligand solutions were prepared at a concentration of 15 µM at 
pH 7.8 buffered with 50 mM ammonium acetate with 5 µM magnesium acetate.  The 
solutions were infused via a gold-coated static tip operated between 1.5 and 1.7 kV at a 
capillary temperature of 200°C. The pH was adjusted with ammonium hydroxide. All 
experiments were performed on a Thermo Scientific Orbitrap Elite mass spectrometer 
(Bremen, Germany) equipped with a Coherent Excistar 193 nm excimer laser (Santa 
Cruz, CA) and modified to allow UVPD as described previously.42 All mass spectra were 
collected at 240K resolution at m/z 400.  50 scans were averaged for the MS1 spectra. All 
UVPD experiments were performed using a single 3 mJ pulse (without focusing or 
collimation of the laser).  The 8+ charge state of each protein or protein/ligand complex 
was selected for MS/MS analysis using an isolation width of 12.5 m/z. The automatic 
gain control was set to achieve a signal level of 2e5 with a fill time of 1 second for 
UVPD experiments.  The Orbitrap mass analyzer was scanned from m/z 220 to 4000, and 
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750-1000 scans were averaged for each UVPD mass spectrum. Three to four replicates 
were collected for each protein/ligand complex. 
6.3.4 DATA ANALYSIS 
The UVPD mass spectra were decharged using Xtract with a S/N of 2 and a fit 
factor of 44% and remainder of 25%. The monoisotopic ions were then searched against 
the respective K-Ras amino acid sequence using a version of Prosight PC 3.0 modified to 
accommodate UVPD fragmentation. This involves searching for the following ions: (a 
,a•, b, c, x, x•, y, y-1, z). The spectra were also searched by considering all fragment ions 
with a mass shift corresponding to each ligand mass both with and without the 
coordinating Mg2+. The more abundant holo fragment ion species contained the ligand as 
well as the coordinated divalent magnesium for both the GTP and GDPnP complexes of 
each K-Ras variant. GDPnP was used as a stable surrogate of GTP that does not undergo 
hydrolysis. Specifically fragment ion searches undertaken for GDP•Mg2+ complexes 
included the mass shift 462.9781-464.9937 Da and those undertaken for the GDPnP•Mg2+ 
complexes included the mass shift 541.9604-543.9760 Da. For analysis of backbone 
cleavage yields upon UVPD, the abundances of the holo fragment ions were collectively 
summed with the abundances of the corresponding apo ion series. All identified ions 
were normalized to the total ion current of the spectrum to allow direct comparison across 
all spectra. Identified ions (both apo and holo) from N- and C-terminal ions were 
summed together as described in Cammarata et al.,30 unless stated otherwise. In short, 
fragment ions arising from cleavage of the backbone positions between pairs of adjacent 
amino acids in the protein sequence were collectively summed. For example, all N-
terminal product ions (an, bn, and cn ions) arising from backbone cleavages that occur C-
terminal to a specific amino acid were summed with all the C-terminal product ions (xR-
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n+1, yR-n+1 , and zR-n+1 ions) arising from cleavages that occur N-terminal to the same amino 
acid, where n is the residue number and R is the total number of amino acids in the 
protein.  This value is calculated for each amino acid to convey the backbone cleavage 
efficiency adjacent to each particular residue. The determination of analytical 
significance of a change in backbone cleavage efficiency upon UVPD is described in 
Figure 1.  
 
Figure 1. Histogram illustrating determination of significant changes in backbone 
cleavage efficiencies for all calculated changes in fragment ion abundances 
from the UVPD data. Blue bars show the frequency of bin level of the 
change in UVPD backbone cleavage efficiency (considering over 600 
backbone cleavage efficiency values based on aggregation of all four 
proteins), and the red bars show the percent of the total population of 
backbone cleavages that correspond to the indicated changes.  The green 
bars indicate the total additive percentage from small to large changes, thus 
illustrating that only the top 15% of changes in UVPD backbone cleavage 
efficiency are considered significant. Any change greater than an absolute 
signal change of 0.0001% (generally at least a factor of 2X or greater 
change in abundance) falls within the top 15 percent of all variations in 
backbone cleavages and is considered a significant change. 
Crystal structures 4OBE and 3GFT were used for the WT GDP and WT GDPnP models, 
respectively.  Diagrams of the crystal structure (3GFT) of WT K-Ras•GDPnP•Mg2+ are 
shown in Figure 2 to illustrate the helices, loops, switches, and beta strands. 
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Figure 2. Color coded diagram for K-Ras showing various (a) helices, (b) loops and 
switches, and (c) beta strands based on the crystal structure 3GFT. The 
space-filled component represents GDPnP and Mg2+.  Front and back views 
are shown on the left and right.  Note that only switch I, switch II, and loop 
P are formally named in the crystal structure.  The other helices,  loops, 
switches, and beta strands are labelled here  to facilitate discussion of the 
structure.    
6.4 RESULTS 
Solutions containing each combination of K-Ras protein (WT, G12C, G12V, or 
G12S) and one ligand (GDP or GDPnP) were infused using native ESI conditions, and 
the 8+ charge state was subsequently isolated and subjected to 193 nm UVPD to produce 
informative fragmentation patterns. A representative ESI-mass spectrum is shown in 
Figure 3a for WT K-Ras, and the characteristic narrow and low charge state distribution 
(9+, 8+, 7+) is observed.  The types of complexes formed upon addition of GDP or 
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GDPnP to the solutions are displayed in Figure 3b-i, showing the prominent formation of 
ternary complexes containing the protein, the nucleotide, and divalent magnesium.  
 
Figure 3. a) ESI mass spectrum of K-Ras (WT) sprayed  from a 50 mM ammonium 
acetate solution (pH 7.8) and expanded regions covering the 8+ charge state 
for b) WT•GDP•Mg2+ , c) G12C•GDP•Mg2+ , d) G12V•GDP•Mg2+ , e) 
G12S•GDP•Mg2+ , f) WT•GDPnP•Mg2+ , g) G12C•GDPnP•Mg2+ , h) 
G12V•GDPnP•Mg2+  , and i) G12S•GDPnP•Mg2+. 
The 8+ charge state was selected for UVPD owing to its large abundance. Replacement 
of GDP by GDPnP occurred with about 95% efficiency. Each complex of interest was 
isolated and activated by UVPD to generate the MS/MS spectra that are shown in Figure 
4.  The raw UVPD fragmentation patterns were decharged using XTRACT to produce the 
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deconvoluted spectra in Figure 5, with the masses of the fragments extending from very 
low mass up to 11,000 Da.   
 
Figure 4. UVPD mass spectra of K-Ras (8+) activated using a single 3 mj  pulse for a) 
WT•GDP•Mg2+, b) G12C•GDP•Mg2+, c) WT•GDPnP•Mg2+ and d) 
G12C•GDPnP•Mg2+ , e) G12V•GDP•Mg2+, f) G12V•GDP•Mg2+, g) 
G12S•GDPnP•Mg2+ and h) G12S•GDPnP•Mg2+. (i) There is also an 




Figure 5. Deconvoluted UVPD mass spectra of WT K-Ras corresponding to the spectra 
in Supplemental Figure 4 for a) WT•GDP•Mg2+, b) WT•GDPnP•Mg2+, c) 
G12C•GDP•Mg2+ and d) G12C•GDPnP•Mg2+ , e) G12V•GDP•Mg2+, f) 
G12V•GDPnP•Mg2+, g) G12S•GDP•Mg2+ and h) G12S•GDPnP•Mg2+. The 
asterisks indicate deconvolution artifacts at half the mass of the precursor. 
Assignment of the fragment ions and interpretation of the data entailed analysis of both 
the apo (no ligand) and holo (retaining the ligand) product ions, as described in the 
experimental section.  For this analysis, products containing just the nucleotide by itself 
or containing both the nucleotide and magnesium ion(s) were considered. Exhaustive 
searches revealed that more products were successfully identified containing both ligands 
(nucleotide plus Mg2+) for all protein complexes of interest (Figure 6 for WT), and thus 
these products were targeted in the present study. The product ions that were specifically 
searched for the protein/GDP complexes included those incorporating a mass shift of 
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462.9781-464.9937 Da (relative to the apo fragment ions), and those searched for the 
protein/GDPnP complexes included those with a mass shift of 541.9604-543.9760 Da. 
On average, approximately 142 GDP•Mg2+ holo ions and 139 GDPnP•Mg2+ holo ions 
were identified for each protein construct.  
 
Figure 6. Deconvoluted UVPD mass spectra of WT K-Ras corresponding to the spectra 
in Supplemental Figure 4 for a) WT•GDP•Mg2+, b) WT•GDPnP•Mg2+, c) 
G12C•GDP•Mg2+ and d) G12C•GDPnP•Mg2+ , e) G12V•GDP•Mg2+, f) 
G12V•GDPnP•Mg2+, g) G12S•GDP•Mg2+ and h) G12S•GDPnP•Mg2+. 
The asterisks indicate deconvolution artifacts at half the mass of the 
precursor. 
Overall, the net sequence coverage obtained by UVPD of the GDP complexes was 96% 
for each construct and 92% for the corresponding GDPnP complexes upon including both 
apo and holo fragment ions in the searches. Surprisingly, the sequence coverage obtained 
upon UVPD of the 20+ (denatured) charge state of WT K-Ras decreased to 55%. A 
similar drop in coverage has been noted previously upon comparison of UVPD mass 
spectra of native versus denatured proteins in this laboratory.30,32  
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6.5 DISCUSSION 
6.5.1 UVPD of WT K-Ras Complexes:  analysis of holo fragment ions and 
determination of ligand binding sites 
Previously it was shown that analysis of the holo (ligand-containing) fragment 
ions produced upon UVPD of protein-ligand complexes allowed predictions about the 
ligand binding sites.30,33  
 
Figure 7. (a,b,c,d) Relative abundances of the holo  (ligand-containing) fragment ions 
produced upon UVPD  of WT K-Ras and G12C complexes, color coded as 
N-terminal holo fragments (blue traces) and C-terminal holo fragments (red 
traces).  The UVPD fragment ion maps for the  corresponding G12V and 
G12S complexes are shown in Supplemental Figure 7. The abundances are 
plotted relative to the amino acid sequence  along the x-axis to convey the 
relative efficiencies of backbone cleavages adjacent to each residue. Shaded 
regions (blue and lavender shading) highlight the  regions of the most 
notable changes in UVPD fragmentation efficiencies between the GDP and 
GDPnP complexes and are expanded in Supplemental Figure 8.  (e and f) 
The same blue and lavender regions are highlighted on a superposition of 
crystal structures 3GFT (WT K-Ras•GDPnP •Mg2+ complex with green for 
WT K-Ras features and yellow for the GDPnP ligand)  and 4OBE (WT K-
Ras•GDP•Mg2+ complex with turquoise for WT K-Ras features  and pink for 
the GDP ligand). Two rotated views are shown in e and f.  
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This analysis focused on identification of those stretches of the protein for which both N-
terminal and C-terminal holo fragment ions overlapped, thus indicating regions of the 
protein that interacted with the ligand(s) and retained the ligand during fragmentation of 
the protein. Holo fragment ion plots for each protein/ligand combination of WT and 
G12C K-Ras are displayed in Figure 7, and the holo fragment ion plots for the 
corresponding G12V and G12S complexes are shown in Figure 8 with expansions of 
selected regions in Figure 9.  
 
Figure 8. (a,b,c,d) Relative abundances of the holo  (ligand-containing) fragment ions 
produced upon UVPD  of G12V and G12S complexes, color coded as N-
terminal holo fragments (blue traces) and C-terminal holo fragments (red 
traces). The abundances are plotted relative to the amino acid sequence  
along the x-axis to convey the relative efficiencies of backbone cleavages 
adjacent to each residue. Shaded regions (blue and lavender shading) 
highlight the  regions of the most notable changes in UVPD fragmentation 
efficiencies between the GDP and GDPnP complexes and are expanded in 




Figure 9. Expanded regions from Figure 1 and Supplemental Figure 7. Relative 
abundances of the holo-fragment ions produced upon UVPD of WT-K-Ras 
and G12C complexes, color coded as N-terminal fragments (blue traces) and 
C-terminal fragments (red traces).   
To aid visualization of the regions demarcated by the holo fragment ions, the residues of 
particular interest are represented as space-filled models on the crystal structure of the 
protein, as illustrated for WT-K-Ras•GDP•Mg2+ complex in Figure 10 for which the key 
regions are highlighted as purple spheres. In particular, backbone cleavages adjacent to 
the purple amino acids resulted in N-terminal and C-terminal fragment ions (primarily a- 
and x-type ions for UVPD) that retained the GDP•Mg2+ ligand. For the WT-K-
Ras•GDP•Mg2+ complex, backbone cleavages at residues 4, 10-13, 26-28, 49, 112, 121, 
123-125, and 145-147 resulted in overlapping holo fragment ions from both N and C 
terminal ions, and these residues are highlighted in Figure 10. The WT-K-
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Ras•GDP•Mg2+crystal structure (PDB: 4OBE) indicates that residues 13, 15-18, 30, 116-
117, 119, 146 engage in electrostatic interactions with the GDP•Mg2+ ligand.  
 
Figure 10. Space-filling models representing potential GDP•Mg2+ binding residues 
derived from the UVPD fragmentation patterns based on detection of holo 
(GDP-containing) fragment ions from the WT K-Ras•GDP•Mg2+ complexes 
(8+ charge state). The crystal structure represents the GDP-bound WT K-
Ras construct (4OBE, WT K-Ras•GDP•Mg2+) displayed as three views (a) 
top, (b) front side and (c) back side.  The purple-colored residues are ones 
which are derived from the holo (GDP-containing) fragment ions.  Specific 
amino acids are numbered in the crystal structures. Residues labelled in blue 
font indicate residues that exhibit potential ligand binding based on the 
UVPD results but do not appear to interact with the ligand in the 4OBE 
crystal structure.  
Inspection of Figures 7 and 10 indicate that the binding sites revealed from the UVPD 
results based on the formation of holo fragment ions parallel the predicted location of the 
ligand. Each amino acid lies within two to three residues of an amino acid known to 
engage in electrostatic interactions with the ligand, with the exception of three sites found 
from the UVPD data but not predicted from analysis of the crystal structure. These three 
cleavage sites that were indicative of K-Ras/GDP interactions based on the UVPD data 
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included residues 4, 49 and 123-125 (all labelled in blue font in Figure 10). One of these 
predicted sites (123-125) is particularly interesting. This extra site is found on loop H, 
which may be able to fold down and interact with the guanine portion of the GDP ligand, 
thus suggesting that the extended loop conformation modeled in the crystal structure may 
not reflect all of the conformations that play a functional role in ligand binding.  
Evaluation of the holo fragment ions that differ for the K-Ras complexes 
containing GDP versus GDPnP offers insight into changes in the ligand binding mode as 
a function of the ligand identity.   Two major changes are observed in the graphical 
displays shown Figure 7 (comparison of Fig. 7a (WT K-Ras •GDP•Mg2+) to Fig. 7b 
(WT K-Ras•GDPnP•Mg2+), and comparison of Fig. 7c (G12C•GDP•Mg2+) to Fig. 7d 
(G12C•GDPnP•Mg2+)).  Similar plots are displayed in Figures 8 and 9 for complexes 
containing the G12V and G12S variants. These regions of the UVPD data from residues 
15 – 30 (shaded in blue in Figure 7) and 140 – 160 (shaded in lavender in Figure 7) are 
expanded in Figure 9 for all variants.  The first change is noted in the shift of N-terminal 
ions in the stretch of amino acids around 20 to 28 for both the WT K-Ras and G12C 
complexes. N-terminal holo ions arising from backbone cleavages adjacent to residues 
24-28 are observed for the GDP complexes, but these N-terminal ions vanish for the 
GDPnP complexes and instead new N-terminal holo ions that originate from cleavages 
adjacent to residues 20-21 are observed.  The second change is related to the formation of 
C-terminal holo ions in the region spanning residues 145 to 154 for the WT K-Ras, G12C 
and G12V complexes. C-terminal holo ions stemming from backbone cleavages adjacent 
to residues 145-147 are observed for the GDP complexes, but instead C-terminal holo 
ions that arise from cleavage adjacent to residue 154 are observed for the GDPnP 
complexes. We attribute these changes in the UVPD behavior to an alteration of the 
protein conformation that modulates the rigidity/flexibility of those local regions, as 
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consequently reflected in the backbone fragmentation efficiency.  The implication is that 
the change in protein conformation arises from a shift in the ligand binding mode of both 
the phosphate portion and the guanine binding region in the WT K-Ras, G12C, and G12V 
complexes on going from GDP to GDPnP. For the complexes containing the G12S 
mutant, these same variations in the fragmentation patterns were not detected except for 
the formation of a single low abundance C-terminal holo ion arising from cleavage 
adjacent to residue 154. However, the complexes containing the G12S mutant display 
similar holo ion patterns (e.g. the overlap between N and C terminal holo ions seen 
between residues 123-125) that are consistently observed for all variants (Figure 8). 
Furthermore, when these two general regions (spanning residues 15-30 and 140-160) are 
superimposed on the crystal structures (4OBE for the K-Ras •GDP•Mg2+ complexes and 
3GFT for the K-Ras •GDPnP•Mg2+ complex), they appear to interact with one another 
(Figure 7 e,f), supporting the idea of a change in the binding motif upon substitution of 
GDPnP for GDP, one that is consistent across K-Ras variants. 
6.5.2 Changes in UVPD fragmentation upon ligand exchange:  Impact of GDP 
versus GDPnP 
While analysis of the holo fragment ions upon UVPD reveals information about 
the ligand binding sites as described above, analysis of both the holo (with ligand) and 
apo (without ligand) fragment ions provides information about the efficiency of backbone 
cleavage across the protein, a factor that provides conformational information.30,32 Based 
on past evidence, backbone cleavages are enhanced or suppressed upon UVPD depending 
on the flexibility/accessibility of different regions as well as whether those regions are 
shielded by a ligand (i.e. involved in binding interactions with the ligand) or engaged in 
other stabilizing intramolecular interactions. For the present study, we were particularly 
interested in evaluating the changes in backbone fragmentation relative to the impact of 
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the ligand:  GDP versus GDPnP.  Exchanging the diphosphate nucleotide (GDP) for the 
triphosphate surrogate (GDPnP) altered the efficiency of backbone cleavage between 
different residues, as shown in Figure 11 for which the backbone cleavage efficiency 
upon UVPD is graphically displayed relative to each amino acid in the protein (summing 
fragment ions from both N-terminal and C-terminal cleavages on either side of each 
residue and including both holo and apo fragment ions).  
 
Figure 11.  Relative ion abundances of the summed holo and apo fragment ions produced 
upon UVPD  of  complexes containing (a) WT K-Ras, (b) G12C, (c) G12V, 
or (d) G12S and GDP•Mg2+ (blue data trend) or GDPnP •Mg2+ (red data 
trend). The pink, gray, and blue shaded regions indicate regions of change 
specific to the G12X complexes in comparison to the WT K-Ras complexes.  
Upward or downward arrows  adjacent to the shaded sections indicate those 
regions for which UVPD is enhanced  (red) or suppressed (blue) upon 
ligand exchange from GDP to GDPnP.  Relevant loops  and switches are 
labelled underneath  the x-axis using colors corresponding to Supplemental 
Figure 2. Calculated difference plots are shown in Figure 4. 
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Upon overlaying the UVPD trends for the GDP complexes (blue data trends in Figure 
11) and GDPnP complexes (red data trends in Figure 11), many regions of the backbone 
show negligible changes in cleavage efficiency. The visualization of the similarities and 
differences are enhanced via construction of difference plots which are displayed in 
Figure 12.  
 
Figure 12. Plots showing the differences in abundances of fragment ions obtained from 
WT K-Ras and G12X [a) G12C, b) G12V, and c) G12S] complexes 
containing GDPnP or GDP (i.e. differences in abundances of fragment ions 
from cleavages along the backbone of the protein for each complementary 
pair of protein•GDP•Mg2+ and protein•GDPnP•Mg2+  complexes).  The 
difference plots are constructed from the data shown in Figure 3. The 
difference plot for the WT K-Ras complexes (blue) is repeated in each of the 
three plots to facilitate comparisons to each mutant. Shaded regions relate 
directly to Figure 3. Upward or downward arrows  adjacent to the shaded 
sections indicate those regions for which UVPD is enhanced or suppressed 
upon ligand exchange from GDP to GDPnP.  Relevant loops  and switches 
are labelled underneath  the x-axis using colors corresponding to 
Supplemental Figure 2. Representative standard deviations are shown on the 
unprocessed plots in Figure 3.  
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There are small but reproducible variations in backbone cleavage efficiency upon UVPD 
for several regions with respect to the WT K-Ras—particularly related to amino acids 1, 
3, 5-6, 9, 15-16, 20, 28, 30-32, 44, 46, 127, 141, and 154 for which backbone cleavage 
efficiencies increase for the GDPnP complexes relative to the GDP complexes and 
residues 2, 7-8, 11, 18, 24, 73, 102, 121-122, 125-126, 138-139, 147, 155, 157, 159, 160, 
and 164 for which backbone cleavages decrease for the GDPnP complexes relative to the 
GDP complexes.  
 
Figure 13. Expansions of UVPD fragmentation trends (from Figure 3) for specific 
regions along the backbone, particularly  (a,b)  residues 108-155 for WT K-
Ras and the G12C mutant, (c-f) residues 40-60 for all four K-Ras proteins, 
and (g,h) residues 1-20  of WT K-Ras and the G12S mutant.   The complete 
sets of UVPD fragmentation trends for summed holo and apo fragment ions  
are shown in Figure 3. The UVPD fragmentation trends are shown in blue 
for the GDP•Mg2+  complexes and red for the  GDPnP•Mg2+ complexes . 
Upward or downward arrows indicate those regions for which UVPD is 
enhanced  (red) or suppressed (blue) upon ligand exchange from  GDP to 
GDPnP. (averaging over the entire  section of amino acids).  
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The UVPD fragmentation trends are expanded for these regions in Figure 13, and the 
residues are highlighted on the structure of WT K-Ras in Figure 14 for which blue-
colored residues designate a reduction in backbone cleavage (suggesting ligand shielding 
or involvement in new intramolecular interactions) and red-colored residues denote an 
increase in backbone cleavage (suggesting greater flexibility or weakened intramolecular 
interactions) for the GDP versus GDPnP complexes.  Considering all constructs 
analyzed, most of the enhancement in backbone cleavages for the GDPnP complexes 
occurs in the first 50 residues of K-Ras, whereas most of the suppression occurs beyond 
residue 100. We speculate that the observed variations reflect the interplay between the 
known guanine-binding residues (116,119,146), the ribose-binding residues (30,117) and 
the diphosphate-binding residues (13,15-18) of the complexes.  Analysis of the UVPD 
trends in this way suggests that upon exchange of GDP for GDPnP, the guanine-binding 
region interacts more closely with GDPnP (tighter binding; decreased backbone cleavage 
upon UVPD), whereas the phosphate-binding and ribose-binding regions become more 
dynamic (weaker interactions with GDPnP; increased backbone cleavage upon UVPD). 
This hypothesis is further supported by the earlier observations that the abundances of the 
N-terminal holo fragment ions (i.e. ones associated with cleavages adjacent to residues 
14-22) decreased significantly in the phosphate-binding region (Figure 7) going from the 
GDP to GDPnP complexes, suggesting reorientation of this stretch of the protein.  
 134 
 
Figure 14. Space-filling models showing  the suppression (blue residues) or enhancement 
(red residues) of backbone cleavages  upon UVPD relative to ligand 
replacement (GDP versus GDPnP) for complexes containing  (a) WT K-
Ras, (b) G12C, (c) G12V, or (d) G12S constructs. The crystal structure 
represents the GDP-bound WT K-Ras construct from 4OBE. Regions 
shaded in light blue (residues 1-20), pink (residues 40-60) and gray 
(residues 120-150) correspond to the same regions shaded in Figure 3 which 
indicate regions of change specific to the G12X complexes. Cyan circle 
indicates the position of the G12 residue. 
The primary regions of WT K-Ras that undergo the most significant changes in 
backbone cleavage efficiency upon UVPD of the GDPnP versus GDP complexes are 
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close to the ligand in the crystal structure, such as the P-loop (residues 9, 11, and 15-16), 
switch I (residues 30-32, ribose-binding stretch), and H loop (residues 121-122, and 125-
126), for which backbone cleavages were suppressed in the P and H loops and enhanced 
in switch I. Additionally, there are a number of similarities in the backbone cleavage 
efficiencies for the GDP and GDPnP complexes for all K-Ras variants (with some 
exceptions), supporting that the unique changes induced by the G12X mutations are non-
artifactual. The major similarities in the UVPD behavior of the GDP versus GDPnP 
complexes for the four proteins include an enhancement of backbone cleavage in the 
switch I region and suppression of backbone cleavages in loop H (116-125), loop I (143-
150), the P-loop (10-14), and between residues 70-75. Each of these regions is known to 
interact directly with the nucleotide ligand with the exception of residues 70-75. From the 
crystal structures (4OBE and 3GFT in Figure 7e,f), R73 is on the edge of helix B which 
frays upon ligand exchange to GDPnP. UVPD fragmentation is enhanced in the region of 
switch I (residues 27-36) for the WT, G12C and G12S constructs but not the G12V 
construct, giving G12V an additional distinguishing feature.  Additionally, the fact that 
residues on the H loop (116-125) of G12C exhibit a reduction in the UVPD backbone 
cleavage efficiency upon ligand exchange (Figures 11b and  12a and 13b) provides 
support that this loop interacts with the nucleotide in the guanine moiety in the 
G12C•GDP•Mg2+ complexes. Suppression of UVPD-induced backbone cleavages was 
less significant for the G12V complexes than for the WT or G12C complexes, whereas 
there was no change in the UVPD efficiency of G12S in in the H-loop region. Further 
evidence for the H loop/GDP interaction arises from the presence of holo ions containing 
residues 121 and 123-125, a result that was observed for all K-Ras variants. 
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6.5.3 UVPD of WT K-Ras versus G12X Complexes:  Effects of G12C, G12V, and 
G12S mutations   
As noted above, there are many similarities in the UVPD trends for the WT-K-
Ras and G12X complexes upon exchange of GDP for GDPnP. However, there are also 
several distinctive differences in the UVPD behavior that specifically point to the impact 
of the G12X mutations, not the nature of the ligand. These differences are highlighted in 
Figures 11 and 12 for three distinct regions of the proteins along with their general trend 
of enhanced or suppressed UVPD (upward or downward arrows), and the variations in 
backbone cleavage efficiency upon UVPD are expanded in Figure 13. The regions of 
particular interest are comprised of residues 5-20 (highlighted in blue), residues 40-60 
(highlighted in pink) and residues 120-150 (highlighted in grey). Interestingly, the region 
spanning residues 40-60 displayed significant changes in UVPD fragmentation for the 
three mutants (G12C, G12V, G12S) compared to WT K-Ras (shaded in pink in Figures 
11 and 12, and expanded in 13c-f). UVPD fragmentation was enhanced across the 
backbone region covering residues 41-50 after ligand exchange of the G12C and G12S 
complexes. However, UVPD fragmentation was suppressed in this same general region 
for the G12V complexes. The G12C complexes uniquely exhibited suppression of 
backbone cleavages for a large portion of the C-terminus region (Figure 14b, residues 
108-150; the stretch shaded in gray in Figure 11b and Figure 12a and expanded in 
Figure 13b) that was not observed for the WT-K-Ras or other variant complexes (again 
in each case comparing the GDP to GDPnP complexes). UVPD of the G12S complexes 
reveals a unique and significant enhancement in the P-loop (residues 10-14) (shaded in 
blue in Figure 11d and Figure 12c and expanded in Figure 13h) where the mutation has 
occurred. A table of all residues for which UVPD is enhanced or suppressed for each 
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Table 1. Summary of residues for which UVPD is enhanced or suppressed 
A recent study compared the rates of hydrogen/deuterium exchange (HDX) for 
WT K-Ras and G12C complexes containing GDP or GDPnP.47 While these experiments 
did not allow resolution of HDX rates of individual residues, it was determined that 
regions encompassing residues 7-19 and 114-120 exchanged at faster rates upon GDPnP 
ligation, an outcome suggestive of a more open conformation for the GDPnP complexes 
than the corresponding GDP-bound complexes.47 These same two regions (7-19 and 114-
120) also exhibit considerable changes in backbone cleavage efficiencies upon UVPD in 
the present study, thus further supporting that the tertiary structures of the proteins in 
solution are retained in the gas phase. In the same HDX study, one region of K-Ras 
underwent a slower rate of HDX upon GDPnP ligation (residues 38-52).47 This region 
encapsulates the region noted in the present study for which there is a unique change in 
backbone cleavage upon UPVD for the G12X constructs (containing loop C and strand 
B). Although the change in the rate of HDX was small, the underpinning of the 
conformational structural change may be exaggerated upon transfer of the protein to the 
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gas phase from the solution phase or may signify a greater sensitivity of UVPD to small 
conformational changes. 
The commonalties and differences in UVPD fragmentation trends with respect to 
the identity of the amino acid in position 12 (G,C,V,S) are striking. UVPD was enhanced 
in the region spanning residues 40 to 50 when position 12 was occupied by small polar 
amino acids that can form hydrogen bonds (C and S), whereas UVPD was suppressed 
when V, a bulky hydrophobic residue, was located at position 12. The fact that the 
presence of these single mutations alters the observed fragmentation behaviors differently 
reflects the exceptional sensitivity of UVPD to variations in protein structure and is 
consistent with the hypothesis that the identity of the particular substitution at the G12 
position matters with respect to changes in protein structure or dynamics, with possible 
downstream functional effects that could impact the disease phenotype.  
 By using UVPD as a means to reveal subtle structural changes in the K-Ras 
complexes, the biological impact of mutation at residue 12 can be re-visited. As was first 
demonstrated in the homolog H-Ras (93% amino acid identity to K-Ras residues 1-166), 
mutation of the Gly12 site to any amino acid (except Pro) was found to produce an 
activated H-Ras.49 The Gly12 site is situated within van der Waals distance of two 
catalytic residues that stimulate GTP hydrolysis in the complex between H-Ras and the 
GTPase-activating protein p120GAP, so bulkier substitutions at the Gly12 position would 
be expected to inhibit GTP hydrolysis, providing a molecular mechanism to explain H-
Ras activation.50 However, not all biological effects are readily explained by an increase 
in the proportion of Ras found in an activated state.  For example, the particular identity 
of the amino acid substituted at the Gly12 site of H-Ras impacts the morphological 
phenotype of cells transformed with the corresponding genes.49 Specifically for K-Ras, 
G12V and G12D variants were shown to generate distinct differences in the 
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(phospho)proteomic signatures of  colorectal cancer cell lines.51 Also, G12D substitutions 
in K-Ras showed activation of phosphatidylinositol 3-kinase (PI-3-K) and mitogen-
activated protein extracellular signal-regulated kinase (MEK) signaling pathways, but 
G12C and G12V showed activated Ral signaling and decreased growth factor-dependent 
Akt activation, all in a non-small-cell lung carcinoma cell line.52 In the latter case, 
molecular modeling suggested that the different sizes of the substitutions made at the 
Gly12 position may differently impact how the K-Ras variants interact with their 
downstream partners, in this case PI-3-K or itself (homodimerization), which 
subsequently impacts RaLGDS binding.  Techniques to determine how mutations at the 
G12 position affect K-Ras conformation and flexibility would help to better elucidate the 
mechanisms behind differential binding affinity and selectivity.  Towards these ends, 
molecular dynamics and potential mean force simulations of WT K-Ras and the G12D 
variant do suggest that this substitution increases flexibility in three regions: the P-loop 
(residues 10-14) switch-1 (residues 27-36)  and switch-2 (residues 58-64) regions.53 
Notably, these regions are the same, or are in close proximity to sites where enhanced 
cleavage is observed (residues 15-16, 41-48) by the UVPD strategy presented herein.   
The new evidence of structural variations of the K-Ras complexes containing 
single mutations based on the UVPD fragmentation allows further speculation about how 
each mutation might differently modulate the interactions of K-Ras with effector proteins 
(like Raf) as well as influence dimerization of K-Ras which is thought to be essential for 
interaction with Raf dimers for downstream signaling.54,55 For instance, UVPD 
fragmentation was suppressed for the G12C•GDPnP•Mg2+ complex relative to the 
G12C•GDP•Mg2+ complex at the alpha helical interface region which involves alpha 
helices C and D  (residues 86-105 and 126-138).55 While dimers were not probed directly 
in the present study, the suppression of UVPD in alpha helices C and D for the 
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G12C•GDPnP•Mg2+ complex may indicate a stabilization of the alpha helical bundles in 
the monomer, potentially translating to a more stable alpha helical dimer which is the 
putative arrangement adopted for interaction with dimerized Raf.55 In contrast, UVPD is 
suppressed in the effector region of the G12V•GDPnP•Mg2+ complex (relative to 
G12V•GDP•Mg2+) which includes the beta sheet region (such as residues 41-45 of beta 
strand B) and Switch I (residues 27-36) which form the beta interface. While the beta 
interface dimer is not the ideal homodimer for downstream signaling, evidence for higher 
order oligomerization states (Ras nanoclusters), most likely mediated through multiple 
interfaces, has been observed and suggested to be an important determinant in signaling 
output and fidelity.55,  For the third mutant probed (G12S), the increase in UVPD 
fragmentation at the P-loop (residues 8-15), switch I (residues 29-33), and beta strand B 
(residues 37-45) of the G12S•GDPnP•Mg2+ complex (relative to G12S•GDP•Mg2+) 
suggests an increase in flexibility at the beta strand region  in comparison to the G12V 
and G12C mutants. This overall increase in flexibility may serve a dual function to block 
effector binding and additionally to suppress the dimerization at the beta-interface which 
is the incorrect orientation for Raf signaling.55 Although further studies will be required 
to fully characterize the impact of each mutant on K-Ras binding partners, the UVPD-MS 
technique described here clearly reveals the impact of single amino acid changes at the 
G12X position on more distant changes in protein conformation and flexibility. 
6.6 CONCLUSION 
The mutation of K-Ras at the twelfth residue from glycine to cysteine, serine, or 
valine was successfully probed by UVPD mass spectrometry based on comparisons of 
backbone fragmentation efficiencies of complexes containing GDP or GDPnP for all K-
Ras protein variants. Overall, the changes in UVPD fragmentation efficiencies reflect 
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changes in protein conformation that are consistent with crystallographic or other 
experimental data.  The changes in backbone cleavage efficiencies are attributed to 
variations in the flexibility or rigidity of the protein in specific regions, primarily due to 
variations in intra- or intermolecular interactions that are sensitive to single point 
mutations. A series of holo (ligand-containing) ions generated by UVPD offered a 
convenient means to map the GDP or GDPnP binding residues of K-Ras and also 
indicated that residues 121-125 interacted with the guanine portion of GDP or GDPnP.  
There was a notable increase in the UVPD backbone cleavage efficiency within the first 
50 residues of K-Ras upon replacement of GDP by GDPnP, while at the same time there 
was a decrease in backbone cleavage efficiency in the region beyond the 100th residue. 
These two regions are known to interact with the phosphate and guanine portions, 
respectively, suggesting a shift in the binding motif upon the ligand exchange. Most 
importantly, the series of G12X mutations resulted in unique changes in UVPD 
fragmentation of the K-Ras constructs that were significantly different upon ligand 
exchange.  Interestingly, similarities were seen between hydrogen bonding amino acid 
substitutions (C,S) and the bulkier substitution (V). This supports that different K-Ras 
mutations contribute to specific downstream effects based on conformational or dynamic 
changes induced by the mutation. UVPD has proven to be novel structural tool for 
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Chapter 7:  Conclusion 
 
 
Over the course of this dissertation two established methods, crosslinking and 
native mass spectrometry, were improved upon through the incorporation of ultraviolet 
photodissociation (UVPD), an alternative ion activation technique. While the use of mass 
spectrometry to elucidate three-dimensional biomolecule representation remains elusive, 
the techniques that were detailed have the ability to yield distance restraints of residues 
from intra- and inter-protein crosslinking from a top-down perspective as well as use 
native-mass spectrometry to gain detailed information about the location and nature of 
conformational changes of active proteins.  
 While the use of top-down MS for analysis of crosslinked proteins has been 
previously undertaken in other labs, the results were underwhelming. For example, the 
previous studies revealed only two intra-protein crosslinks for the small protein ubiquitin. 
This was due to the lack of separation of the isobaric crosslinked species. Without 
separation the crosslinks are convoluted from the fragmentation resulting in a loss of site-
specific crosslinking information. In the method presented in this dissertation separation 
of crosslinked ubiquitin and hexameric insulin was performed using reversed phase 
chromatography leading to an overall increase, to four, in crosslink identifications for 
ubiquitin and the first example of top-down inter-protein crosslink elucidation of  insulin. 
The inter-protein crosslink elucidation resulted in three total identifications. UVPD was 
also key in identification of said crosslink species whereas collisional activation fell short 
due to lack of sequence coverage as well as undesirable internal fragmentation.  
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 Native mass spectrometry has been a very attractive technique for analyzing 
biomolecules and larger order structures. However, little had been done with regards to 
determining conformational changes of proteins either from ligand exchange, enzymatic 
processes, or amino acid mutations. Throughout Chapters 4-6 these types of specific 
conformational changes were probed by UVPD with a twofold interest. Firstly, to 
determine how sensitive UVPD was to the conformational changes of proteins and 
secondly, to glean biological insights that may not be readily available through 
crystallographic or NMR studies.  
It was shown in Chapter 4 that UVPD successfully can decipher loop-movements 
of DHFR upon inhibition by methotrexate. Upon this realization the method was 
extended to study clinically relevant DHFR mutations from TMP resistant E. Coli 
bacterium. During this analysis size exclusion chromatography was also employed to 
quantify the relative koff rates of each mutant with respect to the substrate, co-factor, and 
its known inhibitors. In the end it was found that by the combined use of UVPD, SEC, 
and kinetic measurements the P21L and W30R mutations promoted TMP resistance 
through two separate mechanisms. A novel propargyl-linked antifolate was also found to 
have potent inhibition of the P21L mutant in comparison to the WT DHFR.  
Finally, in Chapter 6 the oncogene K-Ras was studied. Briefly, UVPD mass 
spectra were collected for both the on and off states of the protein, meaning GDP and 
GTP (GDPnP) bound, respectively. These UVPD spectra were compared to understand 
the conformational changes of the WT protein. Several mutants (G12C, G12S, G12V) 
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were also compared in their on and off states to the WT protein to delineate where the 
mutations caused a difference structure between the two states. It was found that each of 
the mutants effected the proteins’ conformational changes, as detected by UVPD, in 
specific unique regions of the protein. This is suggestive that each of these mutants may 
be driving cancer proliferation through different mechanisms of disease and should be 
treated as unique biological problems to be solved in cancer biology.  
 Through these studies it has been illustrated that native-MS UVPD can be used to 
probe conformational changes due to amino acid mutations and ligand exchange or 
inhibition of proteins in addition to the standard advantages of native-MS for protein 
analysis. These standard advantages include the ability to monitor topology and 
oligomerization of protein complexes as well as to map ligand binding to calculate 
dissociation constants. With these compounded advantages it is now feasible to consider 
applying this method in a high-throughput manner by use of a nano-spray robot such as 
an Advion Nanomate. The objective would be to screen potential inhibitors against an 
assortment of clinical oncomutations to quickly indicate if specific mutations have a 
preference for particular inhibitors over other lead inhibitors. UVPD would be used in the 
same manner as described in Chapter 6 to determine which inhibitors effect the proteins’ 
conformational space and the location of the change. This would be a competitive 
screening method due to the low quantities of proteins and inhibitors as well as data 
analysis that has the potential to be completely automated.  
 Additionally, SEC was found to very useful in comparing the stabilities of 
protein-ligand complexes and should be continued to be used to probe protein-ligand 
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dissociation. It would be useful to develop the analytical method to be quantifiable. It 
would also be interesting to study if ion exchange chromatography would be sensitive 
enough to determine conformational changes based on the protein or protein-complexes 
elution as the concentration of salt is increased while it is interfaced to the mass 
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